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A B S T R A C T
Prostate cancer is the most frequently diagnosed male cancer in the
Western world and a leading cause of cancer-related death in men. In
the search for novel markers for diagnosis and selective targeting of
prostate cancer cells, tumor-specific surface antigens need to be iden-
tified, which discriminate between cancer and benign stem/progeni-
tor cells. The discovery of cell surface markers in prostate cancer in
prostate assists in the discrimination between benign and malignant
stem/progenitor cells at different levels of differentiation. Of partic-
ular interest is the analysis of the precise phenotype of a progenitor
subset, termed Transit-Amplifying Cells (TACs), as both prostate hy-
perplasia and prostate cancer are supposed to develop from these
cells. The main goal of this study is the isolation and characterization
of prostate stem/progenitor cells with particular emphasis on TACs
in order to distinguish between benign and malignant cells. The re-
sults showed that prostate stem/progenitor cells could be isolated
at high purity in the CD49f+Trop-2+ fraction. Moreover, TACs could
be enriched in the CD49f+Trop-2+CD24+ population. These findings
provide a basis for future research in the field of prostate hyperplasia
and cancer biology.
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Z U S A M M E N FA S S U N G
Prostatakrebs ist die am häufigsten diagnostizierte Krebserkrankung
bei Männern in der westlichen Welt und eine Hauptursache der durch
Krebs verursachten Todesfälle. Auf der Suche nach neuen Markern
für die Diagnose und für das Targeting von Prostata-Krebszellen müs-
sen tumorzell-spezifische Oberflächenantigene identifiziert werden,
die möglichst selektiv auf Krebszellen, jedoch nicht auf gutartigen
Prostata-Stammzellen/Vorläuferzellen exprimiert sind. Für die Unter-
scheidung von malignen und benignen Zellen ist jedoch die Kenntnis
des Expressionsmusters on gesunden Zellen Voraussetzung für ein
spezifisches Tumor-Targeting. Von besonderem Interesse ist die Ana-
lyse des genauen Phänotyps einer Progenitorpopulation von Prostata-
zellen, die die so genannten Transit-Amplifying Cells (TACs) enthält,
da angenommen wird, dass sich sowohl die Prostatahyperplasie als
auch der Prostatatkrebs aus diesen Zellen entwickeln. Das Hauptziel
dieser Arbeit ist daher die Isolierung und Charakterisierung von Stam-
m/Progenitorzellen aus Prostata mit Schwerpunkt auf die Charak-
terisierung von TACs, um gutartige von malignen Zellen unterschei-
den zu können. Die Ergebnisse zeigen, dass Stamm/Progenitorzellen
hochrein in der CD49f+Trop-2+ Population angereichert werden kön-
nen. Zusätzlich konnten TACs in der CD49f+Trop-2+CD24+ Fraktion
isoliert werden. Diese Ergebnisse bilden eine Basis für zukünftige
Forschungen auf dem Gebiet der Tumoren und der Hyperplasie bei
der Prostata.
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Satisfaction of one’s curiosity is one of the greatest
sources of happiness in life.
— Dr. Linus Pauling
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I N T R O D U C T I O N
Prostate cancer (CaP) is one of the most prevalent neoplastic diseases
among men and a leading cause of cancer-related death next to lung
cancer. After surgical removal of the prostate or androgen deprivation
therapy, the tumor often turns into a hormone-independent neoplasia
and metastasizes to local or distant lymph nodes and bone tissues.
Existing theories propose that the cause of androgen independence
of CaP is a rare subpopulation of stem-like cells, capable of cancer-
ous growth. However, it has been established that normal prostate
epithelial stem cells exhibit similar androgen independence. Identify-
ing the cancerous subset of cells — and most importantly, distinguish-
ing them from the normal cells — is therefore a major goal in cancer
biology.
The ability to discriminate between normal and cancer stem cells
of the prostate has been a major challenge in recent years. The sub-
set of stem-like cells in normal or benign tissues is characterized by
expression of identical surface molecules with a matching expression
pattern in comparison to malignant tissues. One goal of these experi-
ments is therefore to distinguish normal prostate epithelial and mes-
enchymal stem cells and to provide a definition of prostate cancer
stem cells in terms of surface marker expression. In this study, we
aim at establishing the best isolation procedure for normal prostate
stem and progenitor cell subsets and verify their stem and progenitor
cell features by colony-forming assays, western blot, flow cytometry
and RT-PCR analysis.
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B A C K G R O U N D
2.1 anatomy of the human prostate
The human prostate is an exocrine gland, located in the pelvis and
surrounding the urethra beneath the bladder (Figure 2.1). Its function
is to secrete and store slightly alkaline seminal fluid, which consti-
tutes around 30% of semen. The seminal fluid is generally composed
of simple sugars and two proteolytic enzymes — prostate-specific
antigen (PSA) and prostatic acid phosphatase (PAP) — both of which
are secreted by this gland. According to the McNeal model [79], the
human prostate is anatomically divided into peripheral, central and
transitional zones. Benign prostate hyperplasias usually originate in
the transitional zone, whereas cancer typically develops in the periph-
eral zone [103]. The gland opens into elongated channels which are
gathered out from 12 to 20 small excretory ducts.
Histologically, the prostate exhibits tubuloalveolar gland architec-
ture composed of pseudo-stratified epithelium. The prostate epithe-
lium is embedded in a connective tissue matrix and organized in
ducts that branch out from the urethra and end in the secretory acini.
The epithelium forms a bilayer, consisting of a basal layer of undiffer-
entiated cells close to the basal lamina and a luminal layer of termi-
nally differentiated, column-shaped secretory cells, which are facing
the lumen. Three epithelial cell types can be distinguished: prolif-
erative basal, secretory luminal (both residing in the aforementioned
layers) and a small subset of rare neuroendocrine (NE) cells, scattered
throughout the basal membrane.
The basal cells are immature, highly proliferative cells that express
high molecular weight cytokeratins (CK) 5 and 14, bcl-2, CD44, Ki67,
p63, PCNA, MIT 1 at high levels and CK18 at very low levels. These
cells are androgen independent.
The luminal cells exhibit a strong expression of low molecular we-
ight CK8 and CK18, as well as PSA (prostate specific antigen), AR (an-
drogen receptor) and PAP (prostatic acidic phosphatase). The keratin
expression patterns change upon differentiation and location. The lu-
minal cells are androgen-responsive and they require androgens for
their growth and survival [63].
The neuroendocrine (NE) cells are characterized by expression of
chromogranin A, synaptophysin and NSE (neuro-specific enolase). In
addition, they produce various neuropeptides as serotonin, bombesin,
neurotensin and parathyroid hormone-related proteins [99]. The pro-
teins secreted by NE cells support epithelial growth and viability.
3
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Figure 2.1: Anatomy of the prostate gland.
They are terminally differentiated, but androgen-insensitive and dis-
tributed throughout the basal epithelium, often transversing to lumi-
nal layer.
2.2 evidence for prostate stem cells and markers
Evidence for the existence of a stem cell population within the human
prostate has been presented in the 1980s [24, 25]. Experiments with
murine prostate tissues demonstrate the presence of a small number
of androgen-independent cells, able to reconstitute the whole func-
tional prostate gland. Later experiments showed that both basal and
luminal cells have a common origin [45].
The putative prostate stem cell niche is found in the proximal re-
gion (the region closest to the urethra) [124]. BrdU pulse-chase ex-
periments in mice showed that long term label-retaining cells are lo-
calized proximally to the urethra and revealed the first evidence of
tissue-specific stem cell localization. This region is known to consist
of morphologically distinct stromal cells, which are able to secrete
high levels of TGF-β — a soluble factor, which promotes stem cell
quiescence [96].
Within the prostate epithelium, stem cells were found to be local-
ized in the basal layer [25]. These experiments showed that only cells
from the basal layer preferentially survive androgen ablation. Addi-
tionally, p63-null mice are born without prostate or mammary glands
[62, 103, 104, 65, 25].
When placed in appropriate culturing conditions, prostate epithe-
lial stem/progenitor cells are able to form different colony types.
Hudson et al. proposed two types of 2D colonies — large dense
(type I) colonies and small/intermediate loose (type II) colonies [44].
Guzmán-Ramírez et al. distinguished 3 types of colonies — holo-
clones (type I, i.a. Hudson), paraclones (type II, i.a. Hudson), and
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mesoclones — (intermediate type) [37]. Colonies were grown under
2D (low attachment) and under 3D conditions (Matrigel or Costar
low-attachment plate). The anchorage-independent (3D) growth kept
the cells to maintain their stem cell potential [37, 31, 102]. Recently,
3-dimensional growth of epithelial colonies co-cultured with stromal
cells was reported [136].
Basal layer epithelial stem cells express specific stem/progenitor
cell markers such as Ki67, p63 and bcl-2. p63 encodes two main iso-
forms, transcribed using alternative promoters (TAp63 and ∆Np63).
∆Np63 has multiple functions during skin development and in adult
stem/progenitor cell regulation. It is predominantly expressed in the
basal prostate cells when cultured. The prostate basal cells, but not
the secretory or neuroendocrine cells, express p63 [103, 104, 62]. P63
dimers and tetramers are described in dependence to their activity
and function. The p63 dimers exist in two forms: inactive (dephos-
phorylated) and active (phosphorylated) [21].
Bcl-2 is an anti-apoptotic protein, which is expressed in cells with
long lifespan [1].
CD44 is a single-pass trans-membrane glycoprotein involved in cell-
cell and cell-matrix adhesion and in cell signalling. It is present in
the basal compartment of the prostate epithelium [36, 50]. Its CD44s
splice isoform is present in benign epithelium, while cancer cells over-
express the novel splice variant (v) isoform, CD44v7-10 [47]. There is a
great body of evidence regarding the role of CD44 in different human
cancers and normal tissues. CD44 correlates with stem cell develop-
ment and tumor formation in breast cancer [81, 70, 43, 2], pancreatic
cancer [140], colorectal [23], gastric [38], head and neck [58], ovarian
[101] cancer. In mouse, a single CD44+ cell is sufficient to generate
a complete prostate in vivo [68]. There are contradictory evidences
about CD44 as a stem cell marker in human prostate. Some data show
correlation between CD44+ cells and stemness and tumorigenicity in
prostate cancer cell lines and tumor xenografts [46, 88, 86]. Moreover,
in human prostate cancer and prostate cancer cell lines, CD44 is asso-
ciated with cells of neuroendocrine phenotype [117]. However, there
is an evidence that CD44-negative cells are cells with clonogenic ca-
pacities in human prostate [134].
CD164 is a 80–90 kD sialomucin molecule, highly glycosylated by
both O- and N-linked glycans. The transmembrane forms of CD164
are considered to mediate adhesion and are believed to regulate he-
matopoiesis by facilitating the adhesion of human CD34+ cells to
the bone marrow stroma [132, 131]. There is an evidence that CD164
participates in the localization of prostate cancer cells to the bone
marrow [41]. It is known that mucin expression also influences tumor
progression and metastasis [78]. As most prostate cancer metastases
are located in the bone, the role of this molecule is of interest for
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further investigation. CD164 is reported to be expressed by luminal
cells and subsequently in prostate cancer of luminal origin [73].
Several candidate markers have been reported to isolate stem/pro-
genitor cells in the human prostate — integrin alpha2/beta1 [16, 87],
CD133 [94], CD44 [15, 46, 85], CD49f [34, 134], Trop-2 [34], CD44 and
Ep-CAM [36]. Using immunohistochemical profiling, many authors
have reported the existence of an intermediate phenotype between
basal and secretory epithelial cells [12, 129]. In a recent study by Gold-
stein et al., two fractions of basal cells were identified using the cell
surface marker Trop-2 (Trop-2hi and Trop-2low). They could demon-
strate that only Trop-2hi cells co-expressing CD49f were able to give
rise to high-grade spheres (3-D colonies) [34]. CD49f (integrin α6 sub-
unit) is an adhesion molecule involved in cell-matrix interaction and
together with CD29 functions as a subunit for laminin receptor. In
murine and human prostate Trop-2 is expressed only by the basal
cells of the epithelial compartment [36, 66]. Trop-2, also called tumor-
associated calcium signal transducer 2 (TACSTD2), is a single-pass
type I trans-membrane protein of the Ep-CAM family. However, its
ligand has not yet been identified. Trop-2 is involved in the regulation
of the cell-cell adhesion and is supposed to have similar functions as
Ep-CAM (Trop-1), another molecule from the same family. Trop-2 is
associated with stem cells in human and mouse prostate [34, 31] as
well as in mouse liver (hepatic oval cells) [83]. It is highly expressed
in many tumors including colorectal cancer [56, 133], oral squamous-
cell carcinoma [28] and pancreatic cancer [27].
An additional molecule investigated in prostate biology is CD24.
CD24 was firstly discovered in 1978, when Springer et al. raised rat
anti-mouse antibodies against leucocytes (M1/69 and M1/75) and
later discovered their target molecule. It was named heat-stable anti-
gen, due to its heat resistance [113]. This a cell surface molecule,
which contains a mucin-type glycosylphosphatidylinositol (GPI)-an-
chored region [114]. It is a subject of heavy glycosylation — a process,
which is highly variable in different tissues and cell types and leads to
varied molecular weight of CD24 in the range of 20 to 70 kDa [26, 54].
The mature protein is only 27 to 30 amino acids long, nearly half of
which are serine and threonine residues. They are potential sites for
N- and O-linked glycosylation [4].
CD24 is found to be expressed on various cell types and to con-
duct many functions [26]. The molecule was initially revealed to be a
marker for B-cells. Later it was found to be expressed in neutrophils
and B-cell precursors but not in T-cells or monocytes. On the neu-
trophil surface, CD24 acts as an adhesion molecule by binding to
P-selectin and facilitating the rolling on endothelial cells during the
process of inflammation (as a primary immune response to inflam-
mation).
2.3 cell adhesion molecules 7
Later, CD24 was found to be expressed in neuronal tissue and
in certain types of epithelial cells, for example keratinocytes, renal,
prostate and breast epithelium [8, 97, 59]. More recently, CD24 was de-
scribed as a marker for luminal epithelial cells of the human prostate
[107, 35, 72], as well as a marker of the basal layer of the murine coun-
terpart [66]. Thus, murine colony forming cells are 6-fold enriched in
the CD24+CD49f+ population [66]. CD24 is also expressed by both
basal and luminal epithelial cells of mouse and human mammary
glands [107]. In prostate cancer cells lines CD24 was reported to be
a negative marker for cancer stem cells, whereas it is a marker for
cancer stem cells in ovarian cancer [30], colorectal cancer [138], liver
cancer [67], and pancreatic cancer [69]. We show that CD49f+Trop-
2+CD24+ cells in human BPH and cancer have colony forming and
proliferative potential, which raises the question about the function
and ontogeny of these cells within human prostate epithelium. The
role of CD24 in benign diseases has not been identified. In prostate
and breast cancer CD44+CD24− subset shows phenotype closer to
stem cells. Nevertheless, CD24+ cells are associated with poor prog-
nosis in cancer for prostate [61], breast [2, 81], and other epithelial
malignancies [60]. Moreover, recent studies identified CD24+ tumor-
initiating cells in cancer [30], colorectal cancer [138], liver cancer [67]
and pancreatic cancer [69].
CD24 mediates signal transduction by recruiting Src-family protein
tyrosine kinases (PTK) — c-fgr, lyn and lck, and activates the mitogen-
activated protein (MAP) kinase, recruiting membrane rafts [26]. CD24
is shown to increase the motility and to alter adhesion of several cells;
some of the processes are connected with rearrangement of integrins
[9, 125, 8].
2.3 cell adhesion molecules
The cell adhesion molecules, known as CAMs, are divided into four
major categories: cadherins, integrins, selectins and members of the
immunoglobulin superfamily. The adhesion molecules mediate the
process of cell adhesion through cell-matrix or cell-cell interactions.
Several integrins and cadherins are reported to be expressed in hu-
man epithelium.
2.3.1 Cell-matrix AM (Integrins)
The integrins are a family of transmembrane glycoprotein receptors
that mediate cell-matrix interactions. In humans, 18α and 8β subunits
are present [33]. Each β subunit binds to one of several α subunits
to form a heterodimeric receptor, which is able to detect proteins in
the extracellular matrix. Virtually every cell expresses integrins. Ep-
ithelial cells in adult tissues are generally stationary cells; neverthe-
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less they do express several integrins. Integrins function as signal-
ing molecules as they detect attachment, detachment, and changes in
the local compositions of ligands. Signals initiated by integrins can
modulate epithelial proliferation, differentiation, survival and gene
expression.
2.3.2 Cell-Cell AM (Cadherins)
The classical cadherins are transmembrane adhesion glycoproteins,
which provide homotypic interactions between cells and are used to
maintain cell-cell adhesion or mediate cell migration [118]. These are
calcium-dependent molecules, which intracellularly link to the actin
cytoskeleton with the participation of several molecules (catenins,
p120).
EMT is characterized by reduced E-cadherin and increased N-cad-
herin expression and these changes in the adhesion properties in-
crease the cell motility and invasion capabilities of the cells. Such ex-
pression profile is reported for some tumors and proposed in prostate
cancer. Prostate carcinoma EMT is not well-defined in terms of molec-
ular profiling and expression pattern in the cells. P-cadherin (Plancen-
tal cadherin) is expressed mostly on basal and proliferating layers of
epithelia and its expression decreases during cellular differentiation.
In breast carcinoma, an increased expression is observed and one is
related to a worse prognosis [91]. In benign prostate, P-cadherin is re-
ported as novel basal cell marker [49], having variability of expression
patterns in different CaP [110].
2.3.3 Stage-specific embryonic antigens
Stage-specific embryonic antigens (SSEA) SSEA-3 and SSEA-4 are epi-
topes on related glycosphingolipids, which are termed GL-5 and GL-7
respectively [51]. Glycosphingolipids consist of a carbohydrate moi-
ety or chain linked to ceramide. SSEA-3 and SSEA-4 have been de-
scribed as markers for pluripotency and they are expressed on puta-
tive embryonic stem cells [42]. Recently, however, SSEAs have been
described on variety of tissues on different levels of differentiation.
In human ovaries, small SSEA-4 positive epithelial stem cells have
been identified. SSEA-4 is used to isolate mesenchymal stem cells
[29] and dental pulp stem cells [53] in human, as well as to enrich neu-
ronal progenitors [7]. It is also expressed on epithelial cells of human
cornea, where it is a negative marker for enrichment for stem/pro-
genitor cells [123].
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2.3.4 SUSD2 (W5C5)
SUSD2 stands for Sushi domain containing 2. Its gene is located
in chromosome 22 and encodes an 822-amino acid protein contain-
ing a transmembrane domain and domains with a function close to
cell-to-cell and cell-to-matrix adhesion: somatomedin B, AMOP, von
Willebrand factor type D and Sushi domains. Its function is not well
known. SUSD2 has been recently identified as a novel and specific
marker for prospective isolation of bone marrow-derived mesenchy-
mal stem/stromal cells.[105].
2.4 models of prostate epithelium differentiation
Prostate epithelial stem cells are able to differentiate into luminal (se-
cretory) cells. According to an existing theory, the differentiation pro-
cess links the basal and the luminal cells in a hierarchical manner,
which is confirmed by the identification of immunophenotipically in-
termediate cell types. The process passes through several stages of
differentiation to these intermediate cell types, which reside in the
basal or the luminal layer and express markers typical for both layers.
Immunohistological analyses of human prostate tissue have identi-
fied two intermediate phenotypes based upon cytokeratin expression
patterns that are thought to represent cells of intermediate differen-
tiation stages between basal and luminal cells and possibly resem-
ble progenitor or transit populations [74]. These rare cells co-express
CK5, CK14, and CK18. Some intermediate cells express CK19 and/or
PSCA [122].
Different models for the development of intermediate cells and
their localization exist. Tokar et al. propose a model to distinguish
cells of the basal compartment (PS/P cells and mature basal cells)
and the luminal compartment (luminal cells and intermediate cells)
[120]. In this model, the more mature basal cells play a crucial role in
maintaining the integrity of the prostate and the luminal cell differen-
tiation [11, 62]. Isaacs propose a model of differentiation, in which pu-
tative stem cells divide and differentiate into transit-amplifying (TA)
progenitor cells that give rise to intermediate cells of the luminal com-
partment. These cells possess both basal and luminal characteristics
[48]. According to this view, the luminal intermediate cells are the
direct progenitors of terminally differentiated secretory luminal cells.
Therefore, intermediate cells are supposed to reside in both compart-
ments, in dependence to their differentiation level. The differentiation
from the basal to the luminal compartment is associated with the loss
of basal markers and the acquisition of luminal markers.
Lawson et al. build upon this hypothesis, proposing an additional
hierarchical differentiation of prostate epithelial cells including dif-
ferent intermediate progenitors [66]. The classical linear hierarchical
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model, described in the work of Isaacs and Litvinov, is supported by
the evidence that the intermediate cells express both basal and lumi-
nal markers [71, 48]. Prostate stem cells, which reside in the basal
layer, divide and give rise to transit-amplifying (TA) cells, which ex-
press basal markers and start acquiring luminal markers during their
maturation. These cells, depending on their level of maturation, may
reside in both layers, possess transient self-renewal capacity and pro-
duce terminally differentiated secretory luminal cells. In the bifur-
cated hierarchical model, proposed by Lawson, basal and luminal
cells represent separate epithelial cell lineages. These are supported
by the TA cells or the lineage-restricted basal and luminal cell pro-
genitors. Subsequently, the layer-dependant progenitors differentiate
into basal or luminal terminally mature cells, respectively.
2.5 benign prostate hyperplasia
The characterization of prostate epithelial stem/progenitor cells of
benign prostate hyperplasia (BPH) may provide clues about the eti-
ology and pathophysiology of prostate cancer. Epithelial stem cells
are thought to be involved in the etiology of both BPH and prostate
cancer. BPH is one of the most frequent concomitant anomalies in
elderly men suffering from prostate cancer and is characterized by a
progressive hyperplasia of glandular and stromal tissues mainly in
the transitional zone. As the stromal compartment is reported to be
about two-fold enlarged compared to the epithelial tissue, it is com-
monly regarded as a proliferative stromal disease. Recently, it has
been proposed that BPH stroma is directly influenced by the epithe-
lium via epithelial-mesenchymal transition (EMT) of the basal cells,
which lose their attachment within the epithelial basal layer and their
epithelial phenotype and acquire a mesenchymal phenotype [5].
Inflammation of the prostate is very common in BPH patients and
inflammatory cell infiltrates are confirmed in pathologies in many pa-
tients. Inflammatory infiltrate such as macrophages and lymphocytes
are known to produce growth factors (bFGF, cytokines IL-1 and IL-6)
and pro-inflammatory cytokines in BPH. COX-2, an enzyme, which
converts arachidonic acid to prostaglandins, plays a role in BPH and
has an increased role in the development of the disease. [57]. More-
over, the prostaglandins, which are products of this reaction, play
various roles in mediating and moderating inflammation and are as-
sociated with the progression of BPH [57].
There are many assumptions concerning the aetiology of BPH: al-
teration of stem cell homeostasis [48], embryological reawakening
[55], interaction between epithelium and stroma, inducing cell growth
and prostate-specific differentiation [6], changes of the hormonal lev-
els of androgens and estrogens [40] and inflammation [82].
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2.6 prostate cancer (cap) and cancer metastases
Prostate cancer (CaP) is the most commonly diagnosed cancer among
men. CaP is a malignant tumor of epithelial origin (carcinoma), con-
sidered to be a heterogenous disease. The most common treatment
of prostate cancer is hormonal therapy, which includes androgen ab-
lation and/or employing androgen antagonists for inhibition of the
androgen action [128]. It is very common that after such treatments
the cancer enters a hormone-refractory (androgen-independent) sta-
ge. This evidence prompts the hypothesis that androgen-independent
cancer stem cells may have a key role in the recurrence of prostate
cancer.
It is known that around 30% of the human prostate cancers show
neuroendocrine differentiation [39]. However, the role of neuroen-
docrine cells in cancer development remains unclear to date. These
cells secrete neuropeptides that may contribute to hormone-refractory
prostate cancer and metastasis through paracrine mechanism.
Prostate cancer (CaP) metastasizes preferentially into the skeleton,
causing severe clinical problems: hypercalcemia, bone fractures, and
pain. The metastasizing process goes through a number of steps,
which include detachment of cancer cells from the primary tumor,
migration, adhesion and invasion of cancer cells into the blood or lym-
phatic vessels, extravasations out of the vessel and interactions with
the target tissue. In osseous tissues, the cancer cells interact mainly
with bone-resorbing osteoclasts, feeding them with various stimula-
tory growth factors, such as parathyroid hormone-related peptide,
which leads to disruption of the bone tissue and release of stroma-
bound growth factors. One such factor is transforming growth factor-
β, which in turn stimulates the growth of cancer cells.
Up to 70% of the patients with breast cancer or prostate cancer,
and 15 to 30% of all patients with lung, colon, bladder or kidney
cancer develop osseous metastasis. Once the tumors progress to the
bone, they are incurable [95]. Osseous (bone) metastasis causes severe
bone pain and can result in fractures without any injury, as well as
other life-threatening conditions [137]. There are two major types of
osseous metastasis, one in which bone destruction is the predominant
feature, and another in which new bone formation is predominant.
2.6.1 Role of adhesion molecules in prostate cancer invasion and metastasis
Metastasis requires the interaction of malignant cells with three dis-
tinct microenvironments: (i) the primary organ, (ii) the circulation,
and (iii) the target organ where metastatic lesions will develop. Both
soluble and insoluble stromal elements are involved in the metastatic
cascade [17].
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The extracellular matrix (ECM) is a complex network of proteins
surrounding cells, serving as a structural foundation in tissues. The
interaction of cells with the extracellular matrix is essential for the
organization and maintenance of the tissue architecture and function.
The ECM provides the cells with information about the environment
and in this way influences cell and tissue development. Epithelial
tissues are surrounded by basal lamina (BL), which is a highly struc-
tured form of ECM. The basal lamina is responsible for the compart-
mentalization of the tissue and acts as a barrier stopping cell migra-
tion and invasion. It is built mainly from collagens, elastins, proteo-
glycans; as well as proteins which serve as attachment sites for the
epithelial cells: fibronectin, laminin, vitronectin and entactin.
The ECM of the bone consists of many non-collagenous molecules
such as bone sialoprotein (BSP), osteopontin (OPN), osteonectin, os-
teocalcin, vitronectin and thrombospondin [32]. The basal membrane
of most epithelial tissues is composed of laminin and collagen type
IV (col IV), as well as other collagen subtypes. The prostate epithe-
lial extracellular matrix is known to consist of collagen I and laminin
[115, 126].
Epithelial-mesenchymal transition (EMT) is a process, in which ep-
ithelial cells lose their epithelial phenotype and acquire mesenchymal
characteristics. These changes involve the loss of E-cadherin-mediated
cell-cell adhesion, as well as the cell-to-matrix adhesion. The cells lose
their apical-basal polarity and acquire a motile behaviour with con-
comitant reorganization of the cytoskeleton. EMT plays role in the de-
velopment and the formation of the body and in the differentiation of
multiple tissues and organs. EMT also contributes to tissue repair. Via
still unknown mechanisms, EMT can adversely cause tissue fibrosis
or cancerous processes. Therefore, it is of interest for cancer research
and therapy to gain insight into this process. According to the stem
cell hypothesis, it is believed that stem/progenitor cells are involved
in this process. Therefore, deciphering the role of stem/progenitor
cells would provide key insights to understanding the pathophysiol-
ogy of this process.
Down-regulation of E-cadherin is considered as a hallmark in the
course of EMT. The concomitant increase of vimentin expression is
considered as a reliable marker combination to determine the fate
of EMT. Different E-cadherin repressors are involved directly or indi-
rectly in the process: Snail, Zeb, E47, KLF8 (which repress the activ-
ity of the E-cadherin promoter [90, 130]) and Twist, Goosecoid, E2.2,
FoxC2 (repressing it indirectly) [135, 109]. The loss of apico-basal po-
larity is another crucial step in EMT. In epithelial cells, three protein
complexes participate in the establishment and maintenance of po-
larity: Par, Crubms and Scribble and their expression is regulated by
EMT inducers [80]. Zeb1 directly represses the transcription of cell po-
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larity genes, like Crumbs3 and Pals1-associated tight junction protein
(PATJ) [3, 112].
There is a growing body of evidence that EMT is an important step
in the pathological processes of benign prostate hyperplasia (BPH)
and prostate cancer formation [5, 98]. The molecules involved are cell
surface marker N-cadherin and intracellular markers such as PDGF-
D, NF-kB, Notch-1 and ZEB1. In prostate cancer, the expression of
these molecules is upregulated during EMT. There is an increasing
evidence that androgen deprivation (currently employed in cancer
therapy) causes EMT in prostate cancer [116], supporting the hypoth-
esis that stem/progenitor cells (which are androgen responsive) are
involved in the process. An important question in this regard is to
investigate at which level of progenitor differentiation the disease is
initiated and whether suitable markers exist to monitor malignant
transformation.
2.6.2 Adhesion molecule changes in cancer
The α6β4 protein (CD49f/CD104) is an integrin, whose extracellu-
lar ligand is laminin [100]. This molecule facilitates the linkage be-
tween the cytoskeleton and the extracellular collagen VII network
and is important for maintaining the tissue architecture. It is essen-
tial for the assembly of hemidesmosomes — multiprotein complexes
formed in basal epithelial cells, located close to the basal lamina and
functioning as anchors between the intracellular cytokeratin network
and the extracellular matrix. The expression of α6β4 integrins can
be affected positively or negatively during epithelial tumor progres-
sion. The loss of this integrin is considered to correlate with loss of
hemidesmosomes by the basal cells, which enables tumor migration
and metastasis. Moreover, loss of the α6β4 integrin is associated with
invasive prostate carcinoma [19]. Furthermore, alterations of α6β4 in-
tegrins are evident in early, precancerous PIN lesions. However, the
α6 (CD49f) subunit is upregulated in prostate cancer.
2.7 evidence for cancer stem cells
The cancer stem cells hypothesis says that heterogeneous tumors con-
tain a small subset of stem-like cells of cancer origin, which have
the capacity to retain cancer growth and to allow the cancer to sur-
vive any chemotherapy treatments. These cells are called CSCs (can-
cer stem cells), because they possess properties of the normal stem
cells, as self-renewal and differentiation. Stem cells in tumors were
firstly identified in acute myeloid leukemia and described as express-
ing the phenotype CD34+ CD38− [13]. CSCs have been subsequently
discovered in tumors of different origin, such as breast, prostate, pan-
creas or melanoma.
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Epithelial stem cells are of interest due to their capacity to restore
a certain organ and for their potential role in cancer initiation. Ep-
ithelial cancer stem cells are pointed out as target populations in
sarcomas. Normal prostate epithelial stem cells share the property
of androgen independence with the cancer stem cells, which in turn
are capable of developing the lethal phase of CaP, termed hormone re-
fractory CaP. The identification of this subset of cells, and most impor-
tantly — distinguishing these cells from the normal ones, is a concern
of primary importance in cancer biology.
2.8 stromal cells
The stromal layer of the prostate gland consists of fibroblasts and
smooth muscle cells, mixed with intermediate myofibroblasts. All
stromal cells express vimentin, smooth muscle cells and myofibrob-
lasts also express α-smooth muscle actin (α-SMA). Smooth muscle
myosin and desmin are expressed only by smooth muscle cells. Most
of the stromal cell nuclei in vivo are positive for androgen, suggesting
that the stromal layer is androgen-dependent.
Prostate stromal progenitor cells are able to differentiate into fibrob-
lasts and smooth muscle cells. Transforming growth factor-β (TGF-β)
promotes the differentiation into smooth muscle cells, which is asso-
ciated with the elevated expression of α-SMA and desmin [106]. In
absence of TGF-β, the cells express mainly vimentin and fibronectin,
which corresponds to a fibroblastoid phenotype. Vimentin belongs
to the intermediate filament family. It is highly expressed in mes-
enchymal cells and has been used as a specific mesenchymal marker.
The differentiation of cultured prostatic stromal cells is modulated by
adrenergic receptor antagonists [108, 10], estradiol, dexamethasone
and androgen [139]. During human fetal development we have pre-
viously shown that the prostate undergoes changes mimicking both
cancer as well as benign prostatic hyperplasia. Starting from the sec-
ond trimester there is distinct growth of the fetal prostate exhibiting
an identical histology as seen in the elderly [75]. The same is true for
prostate cancer. 5-α reductase 1 and 2 are key enzymes in prostate
cancer development and both are over-expressed during fetal devel-
opment similar to prostatic neoplasia [76].
3
M E T H O D S
3.1 materials
3.1.1 Laboratory instruments
List of equipment used:
1. BD FACS AriaTM Ilu sorter (Becton Dickinson, Heidelberg, Ger-
many)
2. BD FACS Canto flow cytometry analyser (Becton Dickinson,
Heidelberg, Germany)
3. Bio-Rad SmartSpecTM 3000
4. PerkinElmer Gene Amp. PCR System 2400
5. Roche PCR Light Cycler (Roche, Basel, Switzerland)
6. Microscope Zeiss Axiovert 40C
7. Microscope Zeiss equipped with Sony 3CCD-Iris camera
8. Centrifuge
3.1.2 Software
1. FlowJo software (Tree Star Inc., OR, USA)
2. BD FACSDiva v6.1.3 software (Becton Dickinson, Heidelberg,
Germany)
3. FCS Express 4
4. IrfanView
5. Adobe Photoshop CS2
3.1.3 Laboratory Chemicals
1. Methanol (VWR International, Radnor, Pennsylvania)
2. Ethanol (Merck, Darmstadt, Germany)
3. Roti-Histol (Roth, Cat No 6640.4)
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4. Phosphate Buffered Saline (LONZA, Basel, Switzerland, Cat No
BE17-516F)
5. Ammonium Chloride (STEMCELL Technologies, Vancouver, Bri-
tish Columbia, Canada, Cat No 07850)
6. Tris-Glycine buffer (10X) BioChemica (Applichem, Gatersleben,
Germany, Cat No A1418)
7. Nonfat dried milk powder (Applichem, Gatersleben, Germany,
Cat No A0830)
8. SDS Solution, 10% (Promega, , Manheim, Germany, Cat No
V6553)
9. Tween-20 ((Sigma-Aldrich, St. Louis, MO, USA, Cat No A1379)
10. Pedrogen 30% H202 ((Sigma-Aldrich, St. Louis, MO, USA, Cat
No 31642)
11. Formaldehyde 37% (ROTH, Cat No CP10.1)
12. Precision Plus Protein Dual Standards, (Bio-Rad Laboratories,
Hercules, California, USA, Cat N 161–0374)
13. SIGMA FAST BCIP/NBT (Sigma-Aldrich, St. Louis, MO, USA,
Cat N B5655)
14. DAPI (Sigma-Aldrich, St. Louis, MO, USA, )
15. FDA (Fluorescein diacetate) (Invitrogen, Darmstadt, Germany,
Cat No F1303)
16. Anexin-V-FLUOS (Roche Diagnostics, Mannheim, Germany, Cat
No 11 828 681 001)
17. Target Retrieval Solution (Dako, Glostrup, Denmark, Cat No
S1699)
18. Fluorescent Mounting Medium (Dako, Glostrup, Denmark, Cat
No S3023)
19. Protease inhibitor cocktail tablets, EDTA-free (Roche Diagnos-
tics, Mannheim, Germany, Cat No 11 873 580 001)
20. Bio-Rad Dc Protein Assay Kit, (Bio-Rad Laboratories, Hercules,
CA, USA, Cat No 500-0113)
21. Mini-PROTEAN TGXTM (Bio-Rad Laboratories, Hercules, CA,
USA, Cat No 456-1024)
22. 5-Bromo-2’-deoxyuridine (Applichem, Darmstadt, Germany, Cat
No A2139)
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23. Rhodanile Blue ((Sigma-Aldrich, St. Louis, MO, USA, Cat No
121495)
24. VECTASTAIN ABC Kit Elite (Vector laboratories, Burlingame,
CA, USA, Cat No PK-6200)
25. Avidin/Biotin Blocking Kit(Vector laboratories, Burlingame, CA,
USA, Cat No SP-2001)
26. Peroxidase Substrate Kit (Vector laboratories, Burlingame, CA,
USA, Cat No SK-4100)
27.
3.1.4 Antibodies
3.1.4.1 Antibodies for FACS
See Table 3.1 and Table 3.2.
3.1.4.2 Antibodies for immunohistochemistry
See Table 3.1.
3.1.4.3 Antibodies for western blot
See Table 3.4.
3.1.4.4 Secondary antibodies used in immunohistochemistry and flow cy-
tometry
See Table 3.5.
3.1.5 Materials for methods is molecular biology
3.1.5.1 Primers
See Table 3.6.
3.1.5.2 Reagents
1. Nuclease-Free Water, 1000 ml (Qiagen, Hilden, Germany, Cat
No 129115)
2. RT-PCR Grade water (Life Technologies, Carlsbad, CA, USA,
Cat No AM9935)
3. RNaseZap Rnase Decontamination Solution (Applied Biosys-
tems, Darmstadt, Germany, Cat No 9892G)
4. Deoxyribonuclease I, Amplification Grade (Invitrogen, Darm-
stadt, Germany, Cat No 18068-015)
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Target Fluorochr. Company Host IG class Clone
CD10 PE BD Pharmingen mouse IgG1, κ HI10a
CD13 PE BD mouse IgG1, κ L138
CD15 FITC BD mouse IgM, κ MMA
CD24 PE, APC Miltenyi Biotec mouse IgG1 32D12
CD26 PE BD mouse IgG2a, κ L272
CD29 PE BioLegend mouse IgG1, κ TS2/16
CD31 PE BD mouse IgG1, κ L133.1
CD41 FITC BioLegend mouse IgG1, κ HIP8
CD44 FITC BD mouse IgG1, κ L178
CD44 FITC, APC e-Bioscience rat IgG2b, κ IM7
CD49a PE BD Pharmingen mouse IgG1, κ SR84
CD49b FITC BD Pharmingen mouse IgG1, κ AK-7
CD49f FITC BD Pharmingen rat IgG2a, κ GoH3
CD51 PE BioLegend mouse IgG2a, κ NKI-M9
CD61 PE BioLegend mouse IgG1, κ VI-PL2
CD90 FITC Miltenyi Biotec mouse IgG1 DG3
CD90 APC BD Pharmingen mouse IgG1, κ 5E10
CD104 FITC BioLegend mouse IgG2a, κ 58XB4
CD105 PE e-Bioscience mouse IgG1 SN6
CD117 PE N/A mouse IgG1 104D2
CD133 PE Miltenyi Biotec mouse IgG1 AC133
CD140b PE BD Pharmingen mouse IgG2a, κ 28D4
CD140b APC BioLegend mouse IgG1, κ 18A2
CD144 PE BeckmanCoulter mouse IgG1 TEA 1/31
CD146 PE BD Pharmingen Mouse IgG1, κ P1H12
Table 3.1: Antibodies used in FACS
5. RNase-free DNase Set (Qiagen, Hilden, Germany, Cat No 79254)
6. RNAsy Mini Kit (Qiagen, Hilden, Germany, Cat No 74104)
7. RNeasy Plus Micro Kit (Qiagen, Hilden, Germany, Cat No 74034)
8. RNA Clean and ConcentratorTM-5 (Zymo Research, Irvine, CA,
USA, Cat No R1015)
9. ImProm-IITM Reverse Transcription System (Promega, Manheim,
Germany, Cat No A3800)
10. Recombinant RNasin®Ribonuclease Inhibitor (Promega, Man-
heim, Germany, Cat No N2511)
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Target Fluorochr. Company Host IG class Clone
CD164 PE BD Pharmingen mouse IgG2a, κ N6B6
CD200 PE BD Pharmingen mouse IgG1, κ MRC OX-104
CD271 APC Miltenyi Biotec mouse IgG1 ME20.4-1.H4
CD324 Alexa 488 Biolegend mouse IgG1, κ 67A4
CD325 APC e-Bioscience mouse IgG1, κ 8C11
CD326 Alexa 488 Biolegend mouse IgG2b, κ 9C4
CDCP1 PE BD Pharmingen mouse IgG1, κ cub1
Her-2 PE BD mouse IgG1, κ Neu 24.7
Her-3 APC Biolegend mouse IgG1, κ 1B4C3
SSEA-3 PE BD Pharmingen rat IgM MC-631
SSEA-4 PE BD Pharmingen mouse IgG3 MC813-70
TRA-1-60 PE BD Pharmingen rat IgM,κ TRA-1-60
TRA1-81 PE BD Pharmingen mouse IgM,κ TRA-1-81
TROP-2 FITC, APC R&D Systems mouse IgG2a 77220
CD344 PE Biolegend mouse IgG1, κ CH3A4A7
SUSD2 PE Miltenyi Biotec mouse IgG1, κ W5C5
TNAP PE Miltenyi Biotec mouse IgG1 W8B2
Table 3.2: Antibodies used in FACS (cont.)
Target Company Host IG class Clone Cat N
CD24 BD Pharmingen mouse IgG2a, κ ML5 555426
CD24 Thermo Scientific mouse IgM,κ SN3b MS1279P1
CD49f BD Pharmingen rat IgG2a, κ GoH3 555734
ALDHA1 Proteintech rabbit IgG Poly 15910-1-AP
CK17 Proteintech rabbit IgG Poly 10164-2-AP
AR Cell Signaling Tech. rabbit IgG D6F11 5153S
CK5 Thermo Scientific rabbit IgG SP27 MA5-16372
CK18 AbD Serotec mouse IgG1 CY90 MCA1864HT
Trop-2 R&D Systems goat IgG Poly AF650
Table 3.3: Antibodies used in immunohistochemistry
11. qPCR Master Mix Plus for SYBR®Green I (Eurogentec, Cat No
RT-SN2X-03+)
12. LightCycler®480 SYBR Green I Master (Roche, Basel, Switzer-
land, Cat No 04707516001)
13. FastStart SYBR Green Master (Roche, Basel, Switzerland, Cat
No 04673484001)
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Target Company Host IG class Clone
beta-tubulin Cell Signaling technologies rabbit IgG 9F3
beta-actin Cell Signaling technologies mouse IgG2b 8H10D10
GAPDH Sigma-Aldrich rabbit IgG Poly
CD24 BD Pharmingen mouse IgG2a, κ ML5
p63 Biolegend rabbit IgG Poly6190
p63 Sigma-aldrich mouse IgG2a 4A4
bcl-2 Dako mouse IgG1, κ 124
CK5 Thermo-Scientific rabbit IgG SP27
Table 3.4: Antibodies used in Western blot
Antibody Host Company Cat N
a-mouse IgG (H+L) Alexa 488 goat Invitrogen A11029
a-mouse Cy3 rabbit Chemicon N/A
a-rabbit IgG (H+L) Cy3 goat Invitrogen A10520
a-rabbit Cy3 goat Invitrogen A10520
a-rabbit IgG (H+L) Alexa 488 goat Invitrogen A11034
a-rat IgG (H+L) Alexa 488 rabbit Invitrogen A21210
a-goat Alexa 488 rabbit Invitrogen A-11078
a-mouse IgM FITC goat N/A N/A
a-mouse IgM+IgG (H+L) Cy3 goat Millipore AP130C
a-rat IgG Cy3 goat Abcam N/A
Table 3.5: Secondary antibodies used in immunohistochemistry and flow cy-
tometry
14. MessageBOOSTERTM cDNA Synthesis from Cell Lysates Kit
(Epicentre Biotechnologies, Cat No MBCL90310)
15. CD24 siRNA, Trilencer-27 (Origene, USA, Cat No SR311132)
16. Lipofectamine RNAiMAX Reagent (Invitrogen, Darmstadt, Ger-
many, Cat No 13778-150)
17. Opti-MEM Medium (Gibco, Paisley, UK, Cat No 31985)
3.1.6 Materials for cell culture
1. RPMI-1640 (PAA, Pasching, Austria, Cat No E15-840)
2. Hank’s BSS (1x) (PAA, Pasching, Austria, Cat No H15-007)
3. Fetal Calf Serum (PAA, Pasching, Austria, Cat No A15-151)
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4. KnockOut Serum Relpacement (Gibco, Paisley, UK, Cat No 10828-
028)
5. CnT12 (CellNTec, Basel, Switzerland, Cat No CnT12)
6. CnT52 (CellNTec, Basel, Switzerland, Cat No CnT52)
7. Trypsin-EDTA (PAA, Pasching, Austria, Cat No L11-003)
8. Amino acids 50X (PAA, Pasching, Austria, Cat No M11-002)
9. Non-essential Amino acids (Gibco, Paisley, UK, Cat No 11140)
10. Accutase (PAA, Pasching, Austria, Cat No L11-007)
11. L-Glutamine 200 mM (PAA, Pasching, Austria, Cat No M11-
004)
12. Penicilin/Streptomicin (PAA, Pasching, Austria, Cat No P11-
010)
13. Gentamicin (PAA, Pasching, Austria, Cat No P11-004)
14. Sodium Pyruvate Solution, 100 mM (PAA, Pasching, Austria,
Cat No S11-003)
15. Gelatine (Biochrom, Berlin, Germany, Cat No L 7230)
16. Gamunex 10% (Telecris Biotherapoietics, Frankfurt am Mein,
Germany, Cat No T100113)
17. Collagenase, from Clostridium histolycum (Sigma, Cat No C9891)
18. Dispase II (Neutral Protease , grade II) (Roche Diagnostics, Mannheim,
Germany, Cat No 11089700)
19. Insulin solution, human (Sigma, Cat No I9278)
20. Androstanolone (Fluka, Netherlands, Cat No 100952529)
21. Cryo-defined Freezing Medium (CellNTec, Basel, Switzerland,
Cat No CnT-CRYO-50)
22. 2-Mercaptoethanol (Sigma, Cat No M-7522)
23. NH OsteoDiff Medium (Miltenyi Biotec, Bergisch Gladbach, Ger-
many, Cat No 130-091-678)
24. NH AdipoDiff Medium (Miltenyi Biotec, Bergisch Gladbach,
Germany, Cat No 130-091-677)
3.1.7 Other materials
1. BD Cytofix/CytopermTM (Becton Dickinson, Heidelberg, Ger-
many, Cat No 554722)
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3.2 patient selection and tissue procession
This study is based on 100 prostate samples from patients with BPH
or prostate cancer, obtained from November 2009 to April 2013 after
transurethral (n=56) or transvesical (n=19) resection of the prostate
or cystoprostatectomy (n=25). Our work was approved by the local
ethics committee (379/2010B02) and all tissue samples were collected
after informed consent. The patients ranged from 26 to 89 years old
in age. In addition, a representative fraction of every fresh tissue
specimen was fixed in formalin, embedded in paraffin, stained with
haematoxylin and eosin, and further examined by an uro-pathologist.
None of the patients, claimed to suffer from BPH, showed any sign of
prostate cancer in routine histological work-up. Initially, 20 samples
were used for FAC sorting and subsequent clonogenicity analysis, 80
samples were used for experiments with primary tissues, as well as
in preliminary experiments.
For the purpose of our study, freshly obtained samples were gath-
ered in sterile containers with collection medium RPMI-1640 (PAA,
Pasching, Austria). Next, the samples were processed mechanically
into 1 mm2 pieces, digested overnight in a medium, containing RPMI-
1640 (PAA, Pasching, Austria), 200U Collagenase IA (Sigma-Aldrich,
St. Louis, MO US), 0.5 mg/ml Dispase II (Roche, Basel, Switzerland),
1 µg/ml DNAse I (Sigma-Aldrich, St. Louis, MO, USA). The incom-
pletely digested acini were additionally processed through 18G and
20G syringe needles. The cell suspension was passed through a nylon
mesh to remove any remaining undigested fragments.
In order to lyse the remaining erythrocytes, the mixture of cells
was incubated in 0.8% ammonium chloride solution (Stemcell Tech-
nologies, Grenoble, France) for 10min on ice. The resulting cell sus-
pension was washed and any undigested debris was removed using
a 40 µm mesh filter. The resulting single-cell suspension was used for
further experiments.
3.3 cell cultivation methods
3.3.1 Epithelial differentiation medium for cultivated epithelial cells
1. Required stocks:
• 0,1M CaCl2 (100×) -1.1g CaCl2 salt in 100 ml dH20
• 10−5M 5-DHT (1000×) — prepared from 10−2 M — 0.00029
g in 10 ml
• CnT52
2. Final preparation (for 50 ml):
• 0.5 ml 0.1 M CaCl2
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• 0.05 ml 10−5 M 5-DHT
• 49.5 ml CnT52
3.3.2 Differentiation medium for cultivated stromal cells
NH OsteoDiff Medium (for osteoblastic differentiation) and NH Adi-
po Diff Medium (for adipocyte differentiation) (Miltenyi Biotec) sup-
plemented with 1% Penicillin/Streptomycin was added to a 24-well
plate with confluent stromal cells in passage 3. The medium was
exchanged every third day. On the 14th day of the differentiation,
Alizarin red and Alkaline phosphatase assays were performed to de-
tect osteoblastic differentiation and on the 21th day — Oil Red O was
used for adipocyte differentiation. As a negative control, used to de-
tect spontaneous differentiation, for each experiment one well was
left with the normal cultivation medium.
For the Alkaline phosphatase assay, a tablet of SIGMA FAST BCIP/
NBT (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 10 ml
dH20 and filtered. The cells were fixed with ice cold methanol (pre-
cooled on -20◦C) and incubated in a freezer for 5 min. The remaining
methanol was removed with double washing of dH20 and the cells
were incubated with SIGMA FAST for 10 min on RT.
3.3.3 Clonogenicity
The colony-forming capacity of primary prostate epithelial cells was
determined by plating defined cell numbers into 6-well culture plates.
On the 14th day of cultivation, colonies containing more than 32 cells
were microscopically scored. Alternatively, the cells were fixed with
3% FA for 10 min and stained with 1% Rhodanile Blue (Sigma-Aldrich,
St. Louis, MO, USA) for 30 min. Plating efficiency was calculated as
the number of counted colonies, divider by the number of cells plated
(500, 1000, 2000) × 100. Colonies were enumerated in duplicate. Three
types of colonies were scored: holoclones, paraclones and mesoclones,
which were determined microscopically, based on their morphology
and cell number. Paraclones were determined as composed of small,
spindle-shaped and scattered cells; the colonies were irregular and
loose, with a cell count of 32–100 cells. Mesoclones were larger, irreg-
ular and loose, composed of scattered cells with different morphology
(spindle-shaped and round) and a count of 100–500 cells. Holoclones
were round-shaped and dense, composed of cells with different mor-
phology and good mutual connections; the cell count was greater
than 500. The enrichment of colonies after cell sorting was calculated
using the following formula:
E =
c/S
c/U
=
U
S
(3.1)
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where c is the number of colonies, S are plated cells in the sorted
fraction and U are the plated cells in unfractionated cells.
3.4 flow cytometry
3.4.1 Detection of apoptosis and viability with annexin V
Annexins are a family of calcium-dependent proteins, which bind
preferentially to the phospholipid phosphatidylserine. Under normal
physiologic conditions, phosphatidylserine is predominantly located
in the inner part of the plasma membrane. When apoptosis is initi-
ated, phosphatidylserine loses its asymmetric distribution across the
phospholipid bilayer and gets translocated to the extracellular mem-
brane. This process prepares the cells as a target of phagocytosis.
Once the phosphatidylserines are located on the outer surface of the
cell membrane, they can be detected by fluorescently labeled Annexin
V.
3.4.2 Fluorescence activated cell sorting (FACS) and flow cytometry anal-
ysis
The primary cells were incubated with 10 mg/ml polyglobin for 15
min on ice to block any non-specific binding to the Fc receptors.
Next, the cells were stained with fluorochrome-conjugated antibod-
ies for 15 min on ice (all antibodies are listed in Table 3.1 and Ta-
ble 3.2). After washing, the cells were stained with 4’, 6-diamidino-2-
phenylindole (DAPI; Sigma-Aldrich, St. Louis, MO, USA) to exclude
non-viable cells from the analysis. Cultured cells were first digested
with Accutase (PAA, Pasching, Austria), washed in FACS buffer (flu-
orescence activated cell sorting buffer) containing Phosphate Buffer
Saline (PBS), supplemented with 1% of fetal bovine serum (FBS) and
0.01% of NaN3 and incubated with polyglobin. Direct staining was
performed as described above. For indirect staining, cells were first la-
beled with the primary antibody (25 µl of culture supernatant). After
washing twice in FACS buffer, cells were then stained with goat anti-
mouse secondary antibody conjugated with R-phycoerythrin (PE) (
Dako Cytomations, Glostrup, Denmark). After washing, the cells were
stained with DAPI prior to flow cytometric analysis. At least 1/x104
cells were analyzed on a BD FACSCanto II flow cytometer (Becton
Dickinson, Heidelberg, Germany). Data was processed using the Flow-
Jo software (Tree Star Inc., OR, USA). Cell sorting was performed on
a FACSAria-II cell sorter (Becton Dickinson, Heidelberg, Germany).
500–2000 cells from the selected populations were sorted into 6-well
plates containing undefined Prostate Epithelial Progenitor cell med-
ium with low pituitary extract (CellNTec, Bern, Switzerland).
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3.4.3 Combined direct and indirect flow cytometry FACS staining
For co-staining of directly labelled and unlabeled antibodies, an alter-
native staining procedure was performed. The prostate cells in sus-
pension were initially incubated with 10 mg/ml polyglobin for 15
min on ice to block any non-specific binding to the Fc receptors. Next,
the unlabeled antibody was incubated for 15 min (25 µl of culture su-
pernatant with 50 µl of cell suspension). After washing twice with
FACS buffer, a secondary antibody was incubated for 15 min. After
the indirect staining, additional blocking for 20 min was performed,
with plain mouse IgG (20 µl, 1:20 dilution). After the blocking, with-
out washing, the directly labelled antibody was incubated for 15 min,
as a fourth step in the staining. All steps were performed on ice. After
the last step, the samples were measured with FACS Canto.
3.4.4 Intracellular staining with BD Cytofix/Cytoperm
1. Blocking of the cells with PG (15 min on ice)
2. Surface staining of the cells (as mentioned in Section 3.4.2)
3. One-step fixation and permeabilization — 100 µl BD Cytofix/-
Cytoperm solution (20 min on ice)
4. Washing with BD saponin-containing buffer (1× solution in
PBS)
5. Primary antibody incubation, 15 min on ice (CK5 1:50)
6. Washing with saponin containing buffer ×2
7. Secondary antibody incubation, 15 min on ice (anti-rabbit AF488
1:500, anti-rabbit Cy3 1:100)
8. Washing with saponin-containing buffer and transfer of the cells
to FACS tubes with BD buffer
3.4.5 Aldefluor assay
The Aldefluor assay was used to compare the ALDH1A1 activity of
the colonies, grown from the two subsets (CD24+ and CD24−). In
order to perform the analysis, Aldefluor kit (StemCell Technologies,
Grenoble, France) was used as prescribed by the manufacturer. The
measurement of specific ALDH1A1 activity was based on the differ-
ence between the presence/absence of the Aldefluor inhibitor diethy-
laminobenzaldehyde (DEAB). For co-expression studies, additional
surface staining with the indicated antibodies was performed after
treatment of the cells with Aldefluor. The stained cells were analyzed
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on a FACSCanto II flow cytometer (Becton Dickinson, Heidelberg,
Germany) using the FlowJo software for data analysis.
3.4.6 Proliferation and cell cycle analysis (BrdU and PI)
Proliferation of the two subsets of interest was examined on culti-
vated cells of the two fractions (with BrdU pulsing) or on primary
cells after FACS sorting (cell cycle analysis with PI). The cells with
or without BrdU pulsing applied (performed for 30 min in the same
medium) were fixed in ice cold 70% ethanol and frozen on -20◦C. An-
tibody against the incorporated BrdU (B44 clone, Becton Dickinson,
Heidelberg, Germany) was used to visualize the cells in a process of
DNA replication. Propidium iodide (Sigma-Aldrich, St. Louis, MO,
USA) was used to fluorescently stain the DNA and thus to label the
cells in different cell cycle stages. The samples were analysed using
BD FACSCanto II flow cytometer (Becton Dickinson, Heidelberg, Ger-
many) and the BD FACSDiva v6.1.3 software.
3.5 dna and rna analysis methods
3.5.1 Quantitative real-time polymerase chain reaction
Total RNA from cultivated cells was isolated using RNeasy Kit (Qia-
gen, Hilden, Germany) and the quantity of the RNA was determined
with Nanodrop2000 (Thermo Scientific, Waltham, MA USA).
PCR allows the rapid amplification of specific DNA fragments from
complex mixtures of DNA molecules. We used several qPCR proto-
cols for mRNA expression analysis from primary and cultivated cells.
The classical qPCR reaction included two steps: (i) cellular mRNA
was reverse transcribed with a reverse transcription kit (ImProm-IITM
Reverse Transcription System from Promega, Manheim, Germany) in
a thermal cycler (Perkin Elmer GeneAmp PCR System 2400). SYBR
Green (qPCR Mastermix Plus for SYBR Green I, Eurogentec, Seraing,
Belgium) was used as fluorescent reporter to determine the quanti-
fied DNA using the Roche LightCycler 480 System. β-actin and 18S
RNA were used as internal controls. The primers and reference se-
quences are described in Table 3.6. Relative mRNA levels were cal-
culated based on threshold of the cycle values (Ct) corrected for the
expression for β-actin and 18S.
The reaction mixture for DNA reverse transcription is:
• 4 µl 5× Puffer
• 1 µl dNTPs
• 2.4 µl MgCl2
• 1 µl RNase inh.
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Primer Sequence
1 CK18 Forward TGATGACACCAATATCACACGA
2 CK18 Reverse GGCTTGTAGGCCTTTTACTTCC
3 CK8 Forward AGGGCTGACCGACGAGAT
4 CK8 Reverse CACCACAGATGTGTCCGAGA
5 SOX9 Forward GTACCCGCACTTGCACAAC
6 SOX9 Reverse TCGCTCTCGTTCAGAAGTCTC
7 AR Forward GCCTTGCTCTCTAGCCTCAA
8 AR Reverse GGTCGTCCACGTGTAAGTTG
9 CK5 Forward GAGCTGAGAAACATGCAGGA
10 CK5 Reverse TCTCAGCAGTGGTACGCTTG
11 CK19 Forward GCCACTACTACACGACCATCC
12 CK19 Reverse CAAACTTGGTTCGGAAGTCAT
13 CK17 Forward TTGAGGAGCTGCAGAACAAG
14 CK17 Reverse AGTCATCAGCAGCCAGACG
15 TP63 Forward TTGAGATTAGCATGGACTGTATCC
16 TP63 Reverse GTTCTGAATCTGCTGGTCCAT
17 PSA Forward GTGCTTGTGGCCTCTCGT
18 PSA Reverse AGCAAGATCACGCTTTTGTTC
19 PSCA Forward AGCTTGAACTGCGTGGATGA
20 PSCA Reverse TTGCACAAGTCGGTGTCACA
21 SOX2 Forward GGGAAATGGGAGGGGTGCAAAAGAGG
22 SOX2 Reverse TTGCGTGAGTGTGGATGGGATTGGTG
23 B-actin Forward AGTCCTGTGGCATCCACGAAACT
24 B-actin Reverse CACTGTGTTGGCGTACAGGTCTT
25 18s Forward CGGCTACCACATCCAAGGAA
26 18s Reverse GCTGGAATTACCGCGGCT
Table 3.6: PCR primers
• 1 µl Reverse transcriptase
• 1 µl Oligo-dt
The standard protocol used for the Real-time PCR reaction was:
1. 2 min at 95◦C (initial denaturation)
2. 45 sec at 95◦C (denaturation)
3. 30 sec at variable temperature (60◦C to 68◦C) (annealing)
4. Variable time (30 sec to 4 min) at 72◦C (elongation)
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5. Variable time (2 to 16 min) at 72◦C (elongation termination)
For qPCR analysis of sorted primary cells, the MessageBOOSTERTM
cDNA synthesis kit (Epicentre, Madison, WI, USA) was used. 3000
cells were FACS sorted, lysed and frozen on -80◦C. Next, mRNA was
reverse transcribed to first strand cDNA synthesis with MMLV re-
verse transcriptase. Second strand cDNA was synthesized with Mes-
sageBOOSTER DNA polymerase. In vitro transcription was conducted
for four hours using MessageBOOSTER T7 RNA Polymerase. The
resulting cRNA was purified and concentrated with RNA Clean &
Concentrator™-5 (Zymo Research Corp, Irvine, CA, USA). An addi-
tional step of reverse transcription was performed before the Real-
time PCR reaction. All Ct values were calculated after normalization
to β-actin.
3.5.2 siRNA Transfection for CD24
Required reagents:
• CD24 siRNA
• Lipofectamine RNAiMAX Reagent
• Opti-MEM medium
For this method, cultivated epithelial cells derived from BPH were
cultivated in a 6-well plate with 2.5 ml of medium (CnT52). One
day before the transfection, a medium without antibiotics was added.
Preparation of the reagents for the transfection:
1. 5.04 µl (30 µg) from each siRNA (A+B+C = siRNA-mix) + 250
µl Opti-MEM were mixed thoroughly in an Eppendorf tube (for
the negative siRNA control, only the scrambled RNA provided
by the kit: 5.04 µl)
2. 5 µl Lipofectamine + 250 µl Opti-MEM were mixed in a separate
tube
3. (1) and (2) were mixed together and pipetted up and down
4. The mixtures were incubated for 20 min RT
5. 500 µl per well were added
3.6 protein purification and analysis
3.6.1 Protein extraction from cultivated cells
Protein lysates were prepared from cell lines grown on variable cell
culture dish formats, depending on the experiment. The cells were
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detached with Trypsin. After stopping the enzyme, the cells were
washed with PBS twice. For the purpose of lysate preparation, an NT-
40 buffer was used and was supplemented with complete Protease-
Inhibitor cocktail tablets (Roche, Basel, Switzerland). Cell lysis was
performed on RT for 3 min, after which the lysates were spinned
on 4◦C on 13000 RPM for 45 min. The supernatants from the NT-
40 lysates were subsequently subjected to quantification and frozen
on -20◦C. The protein concentration was estimated using modified
Bradford method, suitable for lysates with high concentration of de-
tergent.
Reagents for preparation of NT-40 buffer:
• 1.5 ml 5M NaCl (150 mM final)
• 2.5 ml 1M Tris-HCl Lsg. pH 8 (50 mM)
• 0.5 ml NP-40
• 45.5 ml dH20.
3.6.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Separation of proteins by their molecular weight was accomplished
via sodium dodecyl sulphate polyacrylamide electrophoresis (prin-
ciple described by Laemmli). 7.5% precast gels (Mini-PROTEAN®
TGX™Bio-Rad Laboratories, Hercules, California, USA) were used.
To run the protein samples, 5–25 µg sample/lane (depending on the
antibody used) were used, prediluted in Laemmli buffer. Running
Chamber system from Bio-Rad was used for SDS-PAGE separations
as recommended by the manufacturer. Precision Plus Protein Dual
Standards (BIO-RAD Laboratories, Hercules, California, USA) were
loaded together with the protein samples as molecular size standards.
The separation was performed at 100 V and 50 mA for approximately
2 h.
Preparation of the running buffer:
• 50 ml 10× Tris-Glycine
• 5 ml 10% SDS
• fill up to 500 ml dH20.
3.6.3 Transfer of proteins on nitrocellulose membranes
Transfer and immobilization of proteins from gels onto PVDF mem-
branes was accomplished via electroblotting using a Bio-Rad Trans-
ferring Chamber (principle described by Towbin et al.). The transfer
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buffer was prepared freshly and used to generously soak all com-
ponents of the blotting sandwich during assembly. Blotting was per-
formed at 4◦C under stirring for 45 min at 100 V and 400 mA.
Transfer buffer:
• 50 ml 10× Tris-Glycine
• 0.5 ml 10%SDS
• 100 ml Methanol
• 500 ml dH20.
Blocking of unspecific antibody binding to the PVDF membrane
was performed using 5% milk powder. For protein detection, antibod-
ies against CK5 (rabbit IgG, Thermo Scientific, Rockford, IL, USA),
CK18 (mouse IgG1, AbD Serotec, Martinsried, Germany) and p63
(mouse IgG, Sigma-Aldrich, St. Louis, MO, USA) were used. Depend-
ing on the primary antibody, GAPDH (Glyceraldehyde 3-phosphate
dehydrogenase) or β-actin antibodies were used as housekeeping ge-
nes (respectively rabbit IgG, Sigma-Aldrich, St. Louis, MO, USA and
mouse IgG, Stemcell Technologies, Grenoble, France). Dual color west-
ern blot was performed using antibodies, labeled either with IRDye
800CW (green) or IRDye 700CW (red) (LI-COR Biosciences, Lincoln,
NE, USA), and the Li-COR Odyssey system (LI-COR Biosciences, Lin-
coln, NE, USA) was employed for protein band detection and data
analysis. The list of antibodies is specified in Table 3.4.
The antibodies were used in the following concentrations:
• Cytokeratin 5 (rabbit Ab): 1:500 dilution
• Cytokeratin 18 (mouse Ab): 1:200 dilution
• Androgen receptor (rabbit Ab): 1:500 dilution
• P63 (mouse Ab): 1:1000 dilution (5 µl in 10 ml suspension)
• Anti-GADPH (rabbit Ab) — 1:5000 (house keeping gene con-
trol)
• Anti-β-actin (rabbit Ab) — 1:2000 (house keeping gene control)
3.7 immunohistochemistry/immunofluorescence
The adjacent tissue of each FAC sorting was formalin-fixed and paraf-
fin embedded. Sections of 5 µm were deparaffinized and rehydrated
in descending series of ethanol. Antigen retrieval was performed by
heating the sections in 10 mM citrate buffer (pH 6.0). Alternatively for
unmasking of the CD49f antigen, 1% fucine (Invitrogen, Darmstadt,
Germany) treatment was performed. For blocking of any unspecific
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staining we used 10% of serum, obtained from the same species, in
which the secondary antibody is produced (goat, horse or rabbit). For
the purpose of immunofluorescence, secondary Cy3 or Alexa Fluor
488 labeled antibodies (goat or rabbit) were applied; DAPI was used
for nuclei contrastaining.
For DAB immunofluorescence several blocking procedures were
performed in addition — blocking of endogenous peroxidases with
1% H2O2 and blocking of avidin and biotin. The Vectastain ABC kit
(Vector Laboratories, Burlingame, CA, USA) was used for the avidin-
biotin complex (ABC) method according to the manufacturer’s in-
structions. Peroxidase activity was visualized with 3,3’-diaminobenzi-
dine (DAB) (Dako Cytomations, Glostrup, Denmark).
3.7.1 Immunofluorescence protocol
1. Wash twice with PBS
2. Fix with 1% PFA 30 min, RT
3. Wash twice with PBS
4. Cell permeabilization with 0.1% Triton in PBS (stored on 4◦C),
for 20 min
5. Wash twice with PBS
6. The cells were blocked with 10% goat serum in PBS, for 20 min
7. Primary antibody 1 h RT or overnight on 4◦C, the antibodies
were diluted in 0.1% BSA
8. Wash twice with PBS
9. Secondary antibody 1 h RT, Ab in 0.1% BSA and 1:3000 DAPI
10. Wash twice with PBS
11. Mounting with cover slips.
The list of antibodies is specified in Table 3.3. They were used in
the following concentrations:
• Cytokeratin 5 (rabbit Ab): 1:100 dilution
• Cytokeratin 18 (mouse Ab): 1:100 dilution
• Cytokeratin 17 (mouse Ab): 1:100 dilution
• Androgen receptor (rabbit Ab): 1:100 dilution
• CD24 (mouse Ab): 1:50 dilution
• ALDHA1 (mouse Ab): 1:50 dilution
• CD24 (mouse Ab): 1:50 dilution
32 methods
3.8 statistics
The data were described using the mean value of each group, SD
(standard deviation) and SEM (standard error of the mean). One-
way analysis of variance (parametric ANOVA) and Kruskal-Wallis
test (non-parametric ANOVA) were performed for comparison of the
colony forming ability of different FAC sorted subsets, as well as to
compare different colonies for surface marker expression. P-values
<0.05 were considered to represent statistical significance and <0.001
— as highly significant. 18 primary BPH samples were used to com-
pare the colony-forming ability. Additionally, most of the experiments
were performed in a triplicate at minimum.
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Figure 4.1: Design of experiments (explanation is given on page 34)
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Prostate tissue samples were digested overnight and the best condi-
tions were achieved. On the next day, the resulting single-cell suspen-
sion was used for various experiments. Parts from all samples were
paraffin-embedded for further histochemical and immunohistochem-
ical examination.
4.2 flow cytometry testing of primary prostates
The cells from single cell suspensions were FACS tested for surface
marker expression, co-expression between the surface markers, as
well as between the surface markers and intracellular markers.
4.3 experiments on cultivated unfractionated cells
Single-cell suspensions (without FACS separation) were brought into
culture and depending on the selective medium, epithelial and stro-
mal mesenchymal cell cultures were obtained. When the cells reached
confluence, they were replated and after the third passage were tested
for expression of a broad range of surface markers. The purpose of
this procedure was to confirm the epithelial and mesenchymal char-
acter of these cells on one side; and on the other, to discover new
potential markers for prostate progenitor cells.
4.4 facs sorting and experiments with sorted cells
4.4.1 Experiments on cultivated cells after FACS sorting
Different cell subsets have been sorted from single cell suspensions
and were further cultivated for 14–21 days in epithelial medium (CnT-
52, which is described in Chapter 3). On the 14th day, the cells were ex-
amined for their clonogenicity. When confluence was reached (which
is around the 21–24th day), the cells from the colonies were tested
for surface and intracellular markers with FACS, PCR, western blot
and immunofluorescence. Additionally, the cells were examined for
ALDHA1 activity, as well as for proliferation, using PI and BrDU.
4.4.2 qPCR from FACS sorted cells
Subsets of interest were FACS sorted from primary single-cell suspen-
sion and the cells were lysed. Further experiments for intracellular
marker expression and comparison between different subsets were
performed with qPCR.
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R E S U LT S
5.1 cell viability assessment
BPH and prostate cancer samples were collected after prostate trans-
urethral resection or cystectomy. The samples were first digested over-
night at specifically chosen optimal conditions. To select the surviving
cells for further examination, we tested the resulting single-cell sus-
pension for cell viability. A viable population was observed, negative
for both Annexin V and PI, which was found to be appropriate for
further cultivation, functional examination and in vitro assays.
Figure 5.1: Annexin V and PI co-staining for examination of the viability, af-
ter surgery, cells negative for Annexin V and PI were considered
for viable.
5.2 differential growth of colonies
After obtaining single-cell suspensions, the unfractionated cells were
plated on different media to separate them by origin. Two media for
epithelial cell selection (CnT12 and CnT52) and two media for mes-
enchymal cell selection (Knock-out serum-free medium and RMPI-
1640 with 10% FCS) were used to achieve this goal.
Epithelial-like colonies were found to grow best in a defined serum-
free medium (CnT12 and CnT52), rather than a serum-containing one
(RPMI-1640 supplemented with 10% FCS). Conversely, mesenchymal-
like colony formation was more effective in a serum-containing me-
dium (RPMI-1640 supplemented with 10% FCS) compared to the
serum-free setting (KO-DMEM supplemented with human b-FGF) —
Figure 5.2.
We have grown the epithelial colonies in 2D (monolayer) and 3D
(low attachment) conditions (Figure 5.3). When replated, the epithe-
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Figure 5.2: Differential outgrowth of primary prostate cells. Cells from pri-
mary prostate single-cell suspension showed selective growth
serum-free medium: epithelial in CnT12/52, mesenchymal in
RPMI-1640 and KO-DMEM. Prostate spheres were able to grow
in the CnT12/52 only.
lial mass was maintained without decline of the growth for 5–10 pas-
sages. These cells were easy to maintain, freeze and thaw repetitively.
Preliminary results showed that the cultured cells expressed the ep-
ithelial markers CD324 (E-Cadherin), CD326 (Ep-CAM), CD49f and
CD49b and they did not express the mesenchymal markers CD90,
CD325 (N-Cadherin). Low expression of the stromal marker CD49a
was also observed (Figure 5.4).
a b
Figure 5.3: Cultivated prostate epithelial cells cells after being replated: cells
maintain growth in 2-D conditions (a) and 3-D conditions(b).
The mesenchymal colonies were maintained in monolayer condi-
tions for minimum of 5 passages. They were cultivated in RPMI-1640,
supplemented with 10% FCS. Stromal cells possessed a mesenchy-
mal phenotype and a spindle-shaped form. Flow cytometry analysis
confirmed the expression of mesenchymal markers (CD90, CD140b,
CD71, and CD49ahi) and the absence of epithelial markers (CD324,
CD326 and CD49f) — Figure 5.4.
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Figure 5.4: Prostate epithelial and mesenchymal colonies: Cells from the ep-
ithelial colonies (left) expressed the epithelial markers CD324,
CD326,CD49bhi,CD49fhi, whereas cells from the mesenchymal
colonies expressed the mesenchymal markers CD90, CD140b,
CD71, and CD49ahi.
5.3 surface marker study of primary benign and cancer
samples
5.3.1 Surface marker expression study
We examined the expression of various surface markers on primary
prostate cells in an attempt to distinguish the epithelial from the mes-
enchymal phenotypes. A wide range of surface markers was studied,
including previously known markers for prostate stem cell enrich-
ment, markers known to be present on the prostate cell surface, as
well as markers of previously unknown expression on prostate. In
search for novel markers having the ability to enrich for stem cells, a
panel of in-house-produced antibodies was utilized.
We organized the markers in five groups: integrins, epithelial mark-
ers, mesenchymal markers, markers of unknown expression on pro-
state, and antibodies of unknown specificity (corresponding to in-
house antibodies of unknown specificity). The selected integrins were
CD49a, CD49b, CD49f, CD29, CD41, CD51, CD61 and CD104. A few
of them are known to be expressed in the human prostate (CD49a,
CD49b, CD49f and CD104), while others have not been studied yet
in such context (CD29, CD41, CD51 and CD61). All chosen integrins
were expressed on primary prostate cells but with different patterns.
CD29 — the ubiquitous β1 integrin — was present in the majority of
the prostate cells. The rest of the integrins were expressed only on
a subset of all primary prostate cells (originating from patients with
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Figure 5.5: Integrin expression on primary prostate cells. The selected in-
tegrins were CD49a, Cd49b, CD49f, CD29, CD41, CD51, CD61,
CD104. As shown on the figure, all chosen integrins were ex-
pressed on primary prostate cells but with different patterns.
FCS is shown on the x-axis.
Figure 5.6: Epithelial marker expression on primary prostate cells. The se-
lected markers were CD24, Trop-2, E-cadherin, Ep-CAM, Her2
and Her3. As shown on the figure, all chosen epithelial markers
were expressed on primary prostate cells. FCS is shown on the
x-axis.
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Figure 5.7: Mesenchymal marker expression on primary prostate: the se-
lected markers were CD90, CD34, CD140b, N-CAM, CD10, CD56,
CD105. These markers were expressed on primary prostate tis-
sue, except CD56. FCS is shown on the x-axis.
Figure 5.8: Markers of unknown expression on primary prostate cells: SSEA-
4, TNAP, SUSD2, Frizzled-4 and CD15. From the examined mark-
ers, SSEA-4, TNAP, SUSD2 and CD15 were expressed on primary
BPH cells, whereas Frizzled-4 showed no expression.
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Figure 5.9: Expression patterns of in-house antibodies with unknown anti-
gens on primary prostate cells: HEK-3D3, W4A5, W5C4, 7C5G1,
9A3G2, 58b1. W4A5, W5C4, 7C5G1, 9A3G2 and 58b1 (possibly
CD276) were expressed on cell subsets with a different density,
whereas HEK-3D3 was not expressed on primary BPH cells. FCS
is shown on the x-axis
either BPH or prostate cancer), shown on Figure 5.5. It has been pre-
viously reported that CD49b, CD49f and CD104 are expressed on the
basal epithelium of the prostate, where the stem/progenitor cells re-
side. CD49a in contrast is strongly expressed on the stromal compart-
ment cells, which has been demonstrated by subsequent experiments
in this study. CD41, CD51 and CD61 were also examined, but as their
expression pattern does not correlate with the basal phenotype, they
were not considered further. From the list of integrins, CD49f was
chosen for selection of epithelial stem/progenitor cells and CD49a —
for mesenchymal stem/progenitor cells.
The markers, selected as epithelial, included CD24, Trop-2, E-cad-
herin, Ep-CAM, Her2 and Her3. They were all expressed on primary
human prostate cells (BPH) (Figure 5.6), as well as on cultivated ep-
ithelial cells (Figure 5.10).
As mesenchymal markers, CD90, CD34, CD140b, N-CAM, CD10,
CD56, CD105 were selected. These markers were expressed on pri-
mary prostate tissue, except CD56 (Figure 5.7).
Interestingly, SSEA-4, TNAP, SUSD2 and CD15, which possess un-
known expression on prostate, were expressed on primary BPH cells,
while Frizzled-4 was not (Figure 5.8).
Using our in-house antibodies targeting unknown antigens, HEK-
3D3 was not expressed on primary BPH cells, whereas W4A5, W5C4,
7C5G1, 9A3G2 and 58b1 (possibly CD276) were expressed on cell
subsets with a different density (Figure 5.9).
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Figure 5.10: Flow cytometry examination of cultivated prostate epithelial
cells. Cells were examined for expression of a panel of markers.
The epithelial cultivated cells were positive for CD24, Trop-2,
CD49f, CD49b, CD44, CD140b, CD10, CD338, Her2, Her3, Ep-
CAM, E-Cadherin and the antibodies with unknown antigens
58B1 (possibly CD276), 7C5G1, 9A3G2, expressed CD26 and
CD49a at low levels, and showed negativity for CD90, SSEA-
4, CD344 and SUSD2(W5C5).
5.3.2 Study on surface markers of cultivated human prostate epithelial and
mesenchymal cells
In addition, a wide panel of markers have been used to examine the
expression on cultivated epithelial and mesenchymal stromal cells.
The epithelial cells were positive for CD24, Trop-2, CD49f, CD49b,
CD44, CD140b, CD10, CD338, Her2, Her3, Ep-CAM, E-Cadherin and
the antibodies with unknown antigens 58B1 (possibly CD276), 7C5G1,
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Figure 5.11: Flow cytometry examination of cultivated prostate stromal mes-
enchymal cells. Cells were examined for expression of a panel of
markers. The stromal mesenchymal cultivated cells expressed
highly CD13, CD140b, CD44, CD49a, CD146, CD164 and 58b1
(possibly CD276), they did not express the stem cell markers
SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81, the epithelial markers
CD24, E-cad, Trop-2, as well as CD49f. SUSD2 (W5C5), TNAP
(W8B2) and frizzled- 4 were expressed only on specific subsets.
FCS is shown on the x-axis.
9A3G2. They also expressed CD26 and CD49a at low levels, but were
negative for CD90, SSEA-4, CD344 and SUSD2(W5C5) (Figure 5.10).
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The cultivated mesenchymal cells were tested using a large panel of
mesenchymal markers, epithelial markers and markers of unknown
expression. Figure 5.11 shows that CD13, CD140b, CD44, CD49a, CD-
146, CD164 and 58b1 were highly expressed, whereas the stem cell
markers SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 were not expressed.
The epithelial markers CD24, E-cad, Trop-2, as well as CD49f, were
not expressed on these cells. SUSD2 (W5C5), TNAP (W8B2) and frizz-
led-4 were expressed on specific subsets only. Interestingly, CD44 was
highly expressed on 100% of the mesenchymal cells, although it has
been previously reported to be expressed on the basal epithelial cells
of the human prostate. Additional markers expressed on both epithe-
lial and mesenchymal cells were CD164 and CD49b (Figure 5.11).
5.3.3 Coexpression analysis and gating strategy for cell sorting
Next, coexpression analysis was performed, in order to identify po-
tential subsets of stem/progenitor cells. Several markers have been
examined for coexpression with Trop-2 as a known marker for ep-
ithelial cells. These experiments showed that CD24, CD26, SSEA-4,
CD164 and CD15 were epithelial markers, as they were coexpressed
with Trop-2.
CD49f and Trop-2 were used as main surface markers to separate
promising subsets. Those subsets, which section the CD49f+Trop-2+
subset, were regarded as promising, as they could potentially be able
to separate subpopulations with distinct differentiation capacities. A
set of markers was tested in a coexpression experiment with Trop-
2 and CD49f. Two of them were considered to be appropriate for
sectioning the Trop-2+CD49f+ subset: CD24 and SSEA-4. Markers as
TNAP and SUSD2 (W5C5) were excluded, as they do not coexpress
with Trop-2 and they were regarded as appropriate for selection of
progenitor cells originating from the prostate stroma (Figure 5.13).
Using a negative control for flow cytometry, two major subsets
based on CD49f expression were observed: CD49f-positive (corres-
ponds to CD49fhi in the literature) and CD49f-negative (corresponds
to CD49-flow). When the antibody clone GoH3 against CD49f was
used in conjunction with a bright fluorochrome (for example R-PE),
two clear subsets can be distinguished within the positive fraction:
CD49fhi and CD49flow. After gating on the CD49f+ cells, the follow-
ing plot depicted Trop-2 and one additional marker of interest. CD24
and SSEA-4 (4A2B8) were identified to section the basal CD49f+Trop-
2+ subset into two subsets. Different gating strategies were evaluated
and compared in order to discriminate epithelial subsets with various
differentiation profiles within the human prostate. When gating on
Trop-2-positive cells, which comprises the majority of epithelial cells,
two epithelial subsets were observed (CD24+ and CD49fhi). When
gating on both CD49f-positive and negative cells, since CD49f is not
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Figure 5.12: Coexpression of markers with Trop-2 on primary prostate.
CD24, CD26, SSEA-4, CD164 and CD15 were mostly coex-
pressed with Trop-2, which can describe them as mainly ep-
ithelial markers in prostate tissue.
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Figure 5.13: Coexpression of markers with Trop-2 and CD49f. The CD49f+
subset was selected and further shown as a coexpression win-
dow between Trop-2 and another marker. CD24 showed an in-
teresting subset of coexpression of all the markers, whereas the
other markers were excluded.
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Figure 5.14: Gating on CD49f positive and negative cells shows four dif-
ferent epithelial subsets: CD49f+Trop-2+CD24−, CD49f+Trop-
2+CD24+, CD49f−Trop-2+CD24− and CD49f−Trop-2+CD24−
(a). Gating on Trop-2 positive cells displays two epithelial sub-
sets (b).
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Figure 5.15: Flow cytometry coexpression analysis using the surface mark-
ers CD49f, Trop-2 and CD24. When gating on both positive
and negative cells, four different epithelial subsets (coexpressed
with Trop-2) were found: CD49f+Trop-2+CD24−, CD49f+Trop-
2+CD24+, CD49f−Trop-2+CD24− and CD49f−Trop-2+CD24−.
a selective epithelial marker, four different epithelial subsets were
found: CD49f+Trop-2+CD24−, CD49f+Trop-2+CD24+, CD49f−Trop-
2+CD24− and CD49f−Trop-2+CD24− (Figure 5.14). Within the CD49f+
subset, three distinct cell subsets could be identified: CD49f+Trop-
2+CD24− and CD49f+Trop-2+CD24+ (epithelial) and CD49f+Trop-
2−CD24− (non-epithelial). When further gating on CD49fhi and CD49-
flow was performed, the same epithelial subsets (in coexpression with
CD24 and Trop-2) were found to be available with different density
(Figure 5.16).
5.4 further examination of surface markers
5.4.1 CD49b
CD49b is an α2-integrin subunit, present in the VLA-2 (α2β1) inte-
grin. VLA-2 has been previously reported to enrich prostate epithelial
stem/progenitor cells [89, 16]. In our experience, the CD49f+CD49b+
subset enriches colonies, but due to the overlap of their expression,
only CD49f was further used to enrich the stem cells in a combina-
tion with other markers (Figure 5.17). Another valid reason for ex-
cluding CD49b as an epithelial progenitor cell marker was its very
high expression on cultivated stromal cells.
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Figure 5.16: Gating on CD49fhi and CD49flow displays CD24+ subsets with
different density
   a                                                                        b
Figure 5.17: Coexpression of CD49b with CD49f (a) and clonogenicity of
CD49f+CD49b+ subset. the CD49f+ CD49b+ subset enriches
the epithelial colonies (b).
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5.4.2 CD117 and CD133
In line with previous reports [119, 44], the results of this study con-
firm that CD133 and CD117 are not suitable for prostate epithelial
progenitor cell isolation, because they are not consistently expressed
on cells of primary BPH or prostate cancer samples Figure 5.18. In ad-
dition, both markers were not expressed by cultivated epithelial and
stromal cells.
Figure 5.18: Expression of CD133 and CD117. Results showed that both
markers were not consistently expressed on cells of primary
prostate. FCS is depicted on the x-axis.
5.4.3 CD44
The current study shows that CD49f+ cells do not coexpress CD44
in all the examined samples (Figure 5.19). These experiments were
performed with two different antibody clones (L178 and IM7). In 6
samples from BPH or prostate cancer patients, coexpression of the
two markers was not observed.
CD44 and CD49f were previously described as stem cell markers in
human prostate and both of them are expressed in the basal layer. In
our experience, only CD49f+ cells, but not CD44+ cells were able to
grow into monolayer colonies, suggesting that CD44 is not a marker
for stem/progenitor cells in primary prostate. This is in line with
the earlier work of Yamamoto et al.. All costaining experiments were
performed using the right isotype-matched controls.
Interestingly, CD44 was highly expressed on both epithelial and
stromal cultivated cells. As described above, CD44 is a prostate basal
epithelial marker, which explains the basal character of the epithelial
colonies. On the other hand, CD44 is a mesenchymal stem cell marker
in bone marrow. In the current study, CD44 was selectively identified
on prostate epithelial and mesenchymal cells, utilizing two different
antibodies clones: L178 for the stromal mesenchymal and IM7 for the
epithelial cells.
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Figure 5.19: Coexpression of CD44 with the basal markers. Gating on CD49f-
Trop-2+ cells results in the appearance of CD24+ and CD24-
cells, both of which do not coexpress CD44 (a). CD49 and Trop-
2 were not coexpressed with CD44, whereas CD24 was coex-
pressed with CD44 in a very small subset (b).
5.5 facs sorting of the promising populations
After evaluation of the coexpression profiles, promising populations
were cell sorted for examination of their clonogenicity. The growth
capacity of primary prostate cells from 18 primary BPH samples
and 2 prostate cancer samples and their ability to form epithelial
colonies was analyzed. Cells plated at a density of 200 cells/cm2
gave rise to a frequency of clonogenic cells of up to 1/2000. In pre-
liminary experiments, the colonies were able to grow exclusively in
the CD49f+CD49b+ subset (Figure 5.17) and in the CD49f+Trop-2+
subset (Figure 5.20), in line with the previously published data [34,
31]. A 12-fold enrichment of epithelial colonies was observed in the
CD49f+Trop-2+ subset, which was used as a main subset in the cur-
rent study (Figure 5.20). To further discriminate between more ma-
ture and more primitive progenitors, two additional markers are ap-
plied for investigation: CD24 and SSEA-4.
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Figure 5.20: Clonogenicity of CD49f and Trop-2 positive cells. The colonies
were able to grow exclusively in the CD49f+Trop-2+ subset
with 12-fold enrichment. The CD49f− and CD49f+Trop-2− sub-
sets did not show any epithelial growth.
With regards to the expression of the markers of interest on pri-
mary prostate cells, Table 5.1 shows that Trop-2 is expressed on 20.4
±2.3%, CD49f on 24.7±3.3%, CD24 on 8.3±0.8% and SSEA-4 2.6±2.0%
of total cells.
After gating on the CD49f+ subset and employing Trop-2 and CD24,
three distinct cell subsets could be identified: CD49f+Trop-2+CD24−,
CD49f+Trop-2+CD24+ and CD49f+Trop-2−CD24−. Of these, only the
CD49f+Trop-2+ cells were able to give rise to colonies. The average
fraction of CD49f+Trop-2+CD24− cells was 9.4±2.3% of total cells,
whereas CD49f+Trop-2+CD24+ cells comprised only 1.3±0.3%.
Further sorting of the CD49fhi and CD49flow depicted epithelial
growth in both subsets. Therefore, only the CD49f+Trop-2+ cells were
able to give rise to colonies (in our experience both CD49fhi and
CD49flow). In subsequent studies, the CD24+ and CD24− subsets were
analyzed in more detail using 3-color immunofluorescence, cell sort-
ing and colony forming assays.
5.5.1 Localization of the examined markers
It was previously reported that CD49f and Trop-2 are expressed in
the basal epithelium [34, 31], which is confirmed in the current study
using a set of immunofluorescence experiments. In all BPH samples
examined with flow cytometry analysis, a CD24+-positive subset was
found to be coexpressed with CD49f, which is strongly considered to
be a marker of the basal layer in human and murine prostates [66, 36].
In the current experiments, the localization of CD49f was confirmed
to be within the basal compartment, while of CD24 and Trop-2 — in
the basal and luminal layer (Figure 5.21). Within the luminal layer,
Trop-2 was highly expressed in the proximal compartment, which
corresponds to the luminal intermediate cells, whereas it was not
found in the distal compartment, which corresponds to the termi-
nally differentiated luminal secretory cells. SSEA-4 was found to be
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% of expr. in BPH Gated on CD49f % of all viable cells
sample CD24 Trop-2 CD49f CD24+ CD24− CD24+ CD24−
1 16.0 18.3 4.2 2.9 20.1 0.1 0.8
2 10.6 6.5 10.6 0.8 8.9 0.1 0.9
3 12.6 11.7 25.6 0.4 8.1 0.1 2.1
4 6.1 8.3 1.5 6.6 18.8 0.1 0.3
5 6.8 14.6 20.4 1.1 26.8 0.2 5.5
6 9.3 13.9 28.3 5.3 22.4 1.5 6.3
7 3.2 14.9 19.8 1.0 25.9 0.2 5.1
8 3.4 22.5 26.6 2.2 36.5 0.6 9.7
9 9.6 30.7 29.9 7.0 52.4 2.1 15.7
10 6.5 34.7 12.3 6.7 30.1 0.8 3.7
11 11.3 26.0 19.9 6.2 21.8 1.2 4.3
12 4.7 5.9 5.6 11.5 12.6 0.6 0.7
13 13.5 25.3 34.5 7.9 28.0 2.7 9.7
14 9.5 33.8 36.9 3.3 48.2 1.2 17.8
15 13.2 13.7 24.4 16.9 15.3 4.1 3.7
16 8.9 9.4 22.6 9.9 22.0 2.2 5.0
17 2.8 31.0 8.0 3.8 59.6 0.7 10.7
18 7.8 46.0 54.9 7.7 65.8 4.2 36.1
19 3.6 24.3 54.6 3.2 54.2 1.7 29.6
20 2.5 24.9 51.1 2.4 60.9 1.2 31.1
21 11 11.5 30.9 6.7 14.3 2.1 4.4
Mean 8.3 20.4 24.7 5.3 30.6 1.3 9.4
SEM 0.8 2.3 3.3 0.9 3.9 0.3 2.3
Table 5.1: Marker expression on total unfractionated cells
expressed by the prostate gland epithelium and visualized in the re-
gion between the basal and luminal layer (Figure 5.21). CD164 was
expressed strongly by the luminal compartment of human prostate
(Figure 5.21).
In addition, bcl-2, CK5 and p63 were localized in the basal com-
partment, while androgen receptor (AR) — in the luminal compart-
ment (Figure 5.22). CK17 was a trans-epithelial marker (Figure 5.22).
ALDHA1 was expressed in the basal layer of the epithelial compart-
ment, as well as in the stromal cells, directly surrounding the epithe-
lial acini (Figure 5.24).
5.6 cd24 as a marker of transit-amplifying cells
5.6.1 CD49f+Trop-2+CD24− cells are more clonogenic than CD49f+Trop-
2+CD24+ cells
Eighteen primary BPH and two cancer samples were utilized to per-
form cell sorting in combination with CD24, Trop-2 and CD49f. The
clonogenic capacity of the cells from the resulted subsets was mi-
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Figure 5.21: Expression of surface markers in human prostate. CD49f is lo-
calized in the basal epithelium (a), Trop-2 and CD24 are local-
ized in both basal and luminal compartments (b,c), SSEA-4 was
localized in the gland epithelium, in the region between the
basal and luminal layers (d), CD164 was expressed strongly in
the luminal compartment (d).
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Figure 5.22: Expression of intracellular markers in human prostate. CK17
was a trans-epithelial marker, expressed in both basal and lu-
minal compartments of the prostate epithelium. The markers
bcl-2, CK5 and p63 were expressed in the basal layer of the ep-
ithelium, while androgen receptor (AR) – in the luminal layer.
ALDHA1
Figure 5.23: ALDHA1 expression in human prostate. ALDHA1 was ex-
pressed in the basal layer of the epithelial compartment, as well
as in the stromal cells, directly surrounding the epithelial acini.
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Figure 5.24: ALDHA1 coexpression with CK5(a) and CD24(b). ALDH is not
coexpressed exclusively with CK5 and in the epithelium, it is
spreaded in the stroma (a). ALDH1 shows coexpression wht
CD24 in some cells (b).
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croscopically examined on day 14 after cell sorting. Only cells from
CD49f+Trop-2+CD24− and CD49f+Trop-2+CD24+ subsets, but no oth-
er subsets, were able to grow and give rise to colonies. In 14 FACS
sorted benign samples, clonogenic cells were found in both subsets,
whereas in 4 samples colonies grew only from the CD49f+Trop-2+
CD24− subset.
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Figure 5.25: Clonogenicity of CD24 sorted cells. Only cells from
CD49f+Trop-2+CD24− and CD49f+Trop-2+CD24+ subsets, but
no other subsets, were able to grow and give rise to colonies.
As determined by ANOVA test, the enrichment for colonies in
both subsets was statistically significant, when compared with the
unfractionated cells (Figure 5.25). On average, colonies were enriched
14.3 times in the CD49f+Trop-2+CD24+ subset and 22.5 times in the
CD49f+Trop-2+CD24− subset. The ANOVA test did not confirm sta-
tistical differences in the number of colonies derived from the CD49f+
Trop-2+CD24− and CD49f+Trop-2+CD24+ subsets. These results de-
monstrated a tendency that the CD24− subset was capable of forming
more colonies in comparison to the CD24+ subset by a 1.6-fold factor.
CD24− cells are able to grow into colonies at an approximately 1.6
fold increased proliferation rate compared to the CD24+ cells. Our
data are based on the examination of 18 samples from primary BPH.
Independently of this high number of samples, we were unable to
present reliable statistical measures, but rather a general tendency
(Figure 5.26). The data is not directly comparable, due to the existence
of confounding factors, such as age and health conditions, as well
as systematic errors inherent to the method. The variance between
different patient samples might also be influenced by factors such as
tissue treatment and handling procedures.
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Figure 5.26: Clonogenicity of the two subsets, presented separately for the
18 patient samples. In eight samples the clonogenic potential of
the CD49f+Trop-2+CD24− and CD49f+Trop-2+CD24+ subsets
was similar, seven samples cells of the CD49f+Trop-2+CD24−
subset gave rise to increased colony numbers, and in four sam-
ples only cells from the CD49f+Trop-2+CD24− fraction were
able to form colonies.
Based on the heterogeneous clonogenic capability of the cells in the
CD24+ subsets, three groups in the examined tissue samples could
be distinguished. In eight samples the clonogenic potential of the
CD49f+Trop-2+CD24− and CD49f+Trop-2+CD24+ subsets was simi-
lar, seven samples cells of the CD49f+Trop-2+CD24− subset gave rise
to increased colony numbers, and in four samples only cells from
the CD49f+Trop-2+CD24− fraction were able to form colonies (Fig-
ure 5.27). In contrast to the subsets described above, CD49f− cells as
well as CD49f+Trop-2−CD24− cells failed to give rise to colonies in
all examined samples.
In addition, renewal capacity of the two subsets was examined. Two
approaches were used. In the first experiment, single-cell sorting was
performed using a 96-well plate, in order to gain a colony from a
cell. Alternatively, colonies from the both examined fractions were
trypsinized using clonal rings. Next, each cell per colony was replated
in another 96-well plate. Further growth was observed in the CD24−
subset only. Moreover, the cells gained from paraclones were not able
to grow into colonies, whereas one single cell from the mesoclones
was able to grow into another mesoclone. Because of the lower plating
rate, holoclones were not able to grow when this approach was used
(Table 5.2).
In the second experiment, cells originating from CD49f+Trop-2+
CD24+ and CD49f+Trop-2+CD24− colonies, were continuously re-
plated in order to measure the differences in their growth. The cell
count was determined in each passage.
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Figure 5.27: Groups of samples based on their clonogenic capability. Three
grous were identified: in eight samples the clonogenic poten-
tial of the CD49f+Trop-2+CD24− and CD49f+Trop-2+CD24+
subsets was similar, seven samples cells of the CD49f+Trop-
2+CD24− subset gave rise to increased colony numbers, and
in four samples only cells from the CD49f+Trop-2+CD24− frac-
tion were able to form colonies.
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P0 P1
11.211 CD24−/low xs 4 -
s 1 -
m 1 1
CD24+ - - -
11.228 CD24−/low xs 2 -
CD24+ m 1 -
11.285 CD24−/low s 1 -
CD24+ xs 1 -
11.282 CD24−/low s 2 -
m 1 1
CD24+ xs 2 -
Table 5.2: Renewal capacity of the CD24+ and CD24− subsets. CD49f+Trop-
2+CD24+ and CD49f+Trop-2+CD24− colonies, were continuously
replated and only the CD49f+Trop-2+CD24− mesoclones were
able to produce new colonies.
The single-cell sorting experiment demonstrated the process of self-
renewal. The capability of a single cell per colony to grow into an-
other colony for 14 days was observed. However, this method disre-
gards any aspects of the cell-to-cell interaction. In many experiments
with handling prostate epithelial cell cultures in this work, density
dependancy of the process of cell growth was observed. This is the
motivation for the inclusion of the second experiment.
5.6.2 CD24+ and CD24− colonies show a similar basal phenotype
Cells derived from FACS sorted CD49f+Trop-2+CD24− and CD49f+
Trop-2+CD24+ colonies were examined for expression of trans-epi-
thelial, basal and luminal markers. Firstly, the three types of colonies
(holoclones, mesoclones and paraclones) were examined and all of
them expressed CK5 strongly and CK18 weakly (Figure 5.28).
Secondly, the cells from both fractions expressed CD24, CD49f, Trop-
2 and CD44 at very high levels (90–100% positive cells). Remarkably,
the cells derived from the CD49f+Trop-2+CD24− subset were also
positive for CD24 (Figure 5.29). Moreover, flow cytometry analysis re-
vealed that colonies from both subsets exhibit high expression levels
of epithelial markers (CD49f, CD49b, Ep-CAM, Trop-2, E-cadherin,
Her2 and Her3), low expression of the luminal marker CD26 and
lack of expression of the stromal marker CD90 in both subsets (Fig-
ure 5.29). CD49f, CD49b, Her2 and CD44 are known to be markers
for prostate basal epithelium in human [84]. Therefore, the colonies
derived from both subsets demonstrate a basal phenotype.
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Figure 5.28: Epithelial colonies: paraclones, mesoclones and holoclones. The
three types of colonies are defined on the number of cells and
showed different size and cell density on microscopy. The three
types of colonies showed strong expression of the basal marker
CK5 and and weak expression of luminal marker CK18. CK18
was expressed on cells with very long and spindle-shape scat-
tered and rare neuroendocrine cells.
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Figure 5.29: Flow cytometry analysis shows that colonies derived from
CD49f+Trop-2+CD24− cells and CD49f+Trop-2+CD24+ cells
express high levels of CD49f, Trop-2 and CD24, but are nega-
tive for the stromal marker CD90. The expression is compared
in primary and unfractionated prostate cells (a). Flow cytom-
etry analysis of colonies derived from CD49f+Trop-2+CD24−
and CD49f+Trop-2+CD24+ cells. Cells of both colonies ex-
pressed the epithelial markers Ep-CAM, E-Cadherin, Trop-2,
Her3, CD49f, CD49b, CD44, and Her2 (b). FCS is shown on the
x-axis.
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Real-time PCR analysis of the colonies derived from both subsets
confirmed high expression levels of basal markers (cytokeratin 5 (CK5),
cytokeratin 14 (CK14), p63, SOX9, bcl2a and bcl2b), low expression of
some luminal markers (CK8, CK18, AR), as well as lack of PSA expres-
sion (Figure 5.30 and Figure 5.31). As demonstrated by Western blot
analysis, high expression of CK5, moderate of p63 and very low ex-
pression of CK18 was also detected on protein level in colonies raised
from both subsets (Figure 5.30). In addition, cells from both colonies
were able to proliferate at similar levels, with relatively higher rate for
the CD49f+Trop-2+CD24− colonies over CD49f+Trop-2+CD24+ (Fig-
ure 5.29).
Colonies derived from CD24− and CD24+ cells were examined for
ALDHA1 activity. The results showed that the enzyme-active cells
varied in the order of 10–30% (Figure 5.32). ALDHA1-active cells re-
late to the basal compartment of the human prostate.
5.6.3 The CD49f+Trop-2+CD24+ subset exhibits higher levels of differen-
tiation than the CD49f+Trop-2+CD24− subset
In the search for surface markers able to distinguish between basal
stem/progenitor and early intermediate cells in prostate, four ep-
ithelial subsets were cell sorted, mRNA was amplified and gene ex-
pression analysis using Real-time PCR was performed. The examined
subsets were CD49f+Trop-2+CD24−, CD49f+Trop-2+CD24+, CD49f−
Trop-2+CD24− and CD49f−Trop-2+CD24−. As basal markers, CK5
and p63 were utilized, as intermediate markers — PSCA and CK17
and as luminal markers — CK8, CK18, AR and PSA. CK5 is a marker,
which is supposed to be expressed at highest levels by the cells at
the lowest differentiation stage, whereas p63 is expressed by transit-
amplifying and differentiated basal cells, but not by primitive stem/
progenitor cells [62].
The results presented on Figure 5.33 confirmed the hypothesis that
the CD49f+Trop-2+CD24− cells were the least differentiated in com-
parison to the cells from the CD49f+Trop-2+CD24+ subset. CK5 was
expressed at the highest levels by the CD49f+Trop-2+CD24− sub-
set, whereas the differentiation markers (p63, CK8/18, AR) were ex-
pressed at the lowest level. Moreover, from the four examined subsets,
CD49f−Trop-2+CD24+ showed expression patterns typical for the in-
termediate luminal phenotype, characterized by the highest expres-
sion of luminal markers (CK8, CK18, PSA and AR), as well as more
pronounced expression of the intermediate markers CK17 and PSCA
(Figure 5.33). The lack of expression of CD49f by this subset shows
that it is localized in the luminal layer.
The CD49f−Trop-2+CD24− subset expressed at highest levels the
basal maker p63 as shown on Figure 5.33, indicating that this subset
may contain differentiated basal cells. These results suggest that the
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Figure 5.30: qPCR analysis shows that cells of both groups of colonies ex-
press at high levels the basal makers CK5, p63, bcl2-a and bcl2-b
but low levels of the luminal markers CK8 and CK18 (a). West-
ern blot analysis shows high expression of CK5 and low expres-
sion of CK18 within the colonies derived from both fractions.
The colonies were positive for p63 and CD24, as the results
from PCR (for p63) and flow cytometry (for CD24) show (b).
Relatively higher proliferation of the CD49f+Trop-2+CD24− in
comparison to the CD49f+Trop-2+CD24+ colonies (c)
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Figure 5.31: PCR analysis shows that cells of both colonies express at high
level CK5, bcl2-a, bcl2-b, E-cadherin, p63, low expression of
CK18, no expression of PSA, CK8, SOX2, SOX9; the cells from
CD49f+Trop-2+CD24+ colonies expressed the TA marker p63
and intermediate markers CK17 and CK19 at higher levels.
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Figure 5.32: ALDHA1 activity of CD24+ and CD24− colonies. The results
showed that the enzyme-active cells were presented in both
colonies. The gated controls are visualized on the right.
expression pattern of the CD49f+Trop-2+CD24+ subset is similar to
the one of the transit-amplifying/intermediate basal phenotype.
5.6.4 Localization of CD24 in the human prostate gland
As shown previously in this chapter, CD24 was found to be localized
in both the basal and luminal compartments.
Detailed immunohistochemical studies on different epithelial struc-
tures showed that the expression of CD24 differs depending on the
structures within the prostate gland. Small glandular buds, typical
secretory acini (multi or two layer glands) and main collecting ducts
(two layer glands) were examined. These experiments showed that
CD24 is expressed in both the center and the periphery of the small
glandular buds. Respectively, CD24 is expressed in both basal and lu-
minal epithelium of the glandular acini and only in the luminal layer
of the collecting ducts (Figure 5.34).
5.6.5 CD24 is coexpressed with basal and luminal markers
In primary tissue, a small subset of ALDHA1-active cells coexpressed
CD24, which relates to cells, found to coexpressed CD24 and ALDH1
in basal epithelium (Figure 5.35). Additionally, almost all of the ALDH+
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Figure 5.33: Real-time PCR analysis of marker expression in primary
prostate: CD49f+Trop-2+CD24− and CD49f−Trop-2+CD24−
cells showed expression of basal phenotype markers, whereas
the CD49f+Trop-2+CD24+ showed a basal intermediate pheno-
type and the CD49f−Trop-2+CD24+ — a luminal intermediate
phenotype (a). The 8 markers are shown separately for the four
subsets (b)
cells were positive for CD49f and Trop-2 (Figure 5.35). As CD24 and
Trop-2 are regarded as epithelial markers in the prostate, the coex-
pressed ALDHA1-active cells are therefore localized in the epithelial
compartment.
The coexpression of intracellular CK5 and cell surface CD24 in pri-
mary BPH and cancer tissues was analyzed. A subset of CD24+ cells
showed coexpression of CK5 in all 6 samples (Figure 5.19).
Immunofluorescence analysis of prostate tissues showed coexpres-
sion of CD24 and the basal and intermediate marker CK5 in a few
cells within the basal epithelium [48, 52] and lack of expression of
AR in the basal CD24+ cells Figure 5.38. As previously mentioned in
this section, the CD49f+CK5+CD24+ subset contains approximately
1.3±0.3% of the cells in BPH.
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Figure 5.34: Different epithelial structures and CD24 expression. In small
glandular buds CD24 is located in the center of the bud or in
the basal layer (a,b), in the collecting ducts CD24 is found exclu-
sively in the luminal layer, whereas in the glandular acini CD24
is expressed in both basal and luminal epithelium (d).
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Figure 5.35: ALDH1 expression analysis of defined cellular subsets: subsets
of CD49f+, Trop-2+ and CD24+ cells coexpress functionally
active ALDH1. Almost all of the ALDH+ cells were positive
for CD49f and Trop-2, whereas small subset of ALDHA1-active
cells coexpressed CD24.
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Figure 5.36: CK5 in a coexpression with CD24 in flow cytometry analy-
sis. Gating on CD49f+ cells, CK5 is coexpressed in a subset
with CD24 (left), whereas gating on CD49f− cells, CK5 was not
expressed at all (a), experiments showed that CK5 was coex-
pressed with CD24 within a subset in all the examined 6 sam-
ples (b).
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Figure 5.37: CK5 expression pattern of CD49f+ and CD49f− cells. Gating on
CD49f+ cells, CK5 is coexpressed in a subset with CD24 (left),
whereas gating on CD49f− cells, CK5 was not expressed.
5.7 ssea-4 as a surface marker for subsets at different
stages of differentiation
5.7.1 SSEA-4 is expressed in the prostate epithelium and coexpressed with
epithelial markers
As previously shown in this chapter, the prostate epithelium consists
of cells with different differentiation capacities and the basal epithe-
lium layer is heterogeneous. An additional marker which sections the
CD49f+Trop-2+ basal subset is SSEA-4. Being utilized as a marker for
embryonic stem cells, it is considered to be expressed on cells with
low differentiation. However, our results outline that SSEA-4 is ex-
pressed by the human prostate epithelium.
5.7.2 SSEA-4 negative cells enrich basal colonies in vitro
SSEA-4 is coexpressed with the epithelial marker Trop-2 and it is
expressed within the prostate epithelium, as immunohistochemical
studies show. Cell sortings of SSEA-4+ and SSEA-4− cells within the
CD49f+Trop-2+ subset show that the SSEA-4− cells (CD49f+Trop-
2+ SSEA-4−) are clonogenic (Figure 5.39). This study is based on
FACS sorting of 5 BPH samples, in which experiments 4A2B8 anti-
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Figure 5.38: Immunostaining of CD24 and AR for coexpression. Coexpres-
sion between CD24 and CK5 (b.2) and lack of coexpression of
CD24 and AR were observed (b.1) were observed on some cells.
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Figure 5.39: Clonogenicity of the SSEA-4 cells.Cell sortings of SSEA-4+ and
SSEA-4− cells within the CD49f+Trop-2+ subset show that the
SSEA-4− cells (CD49f+Trop-2+ SSEA-4−) are clonogenic. The
same gating strategy was used – Firstly the CD49f+ were se-
lected and further visualized for Trop-2 and SSEA-4 expression
in a separate dot-blot window.
body against SSEA-4 was used. We consider that the 4A2B8 antibody,
which is raised against iPS cells, recognizes the epithelial compart-
ment of human prostate.
Additional experiments of FACS sorting of CD49f−SSEA-4+, using
the antibody clone MC813-70, show that SSEA-4+ mesenchymal cells
exist. Moreover, the CD49f−SSEA-4+ subset was able to give rise to
mesenchymal colonies (Figure 5.40).
5.7.3 SSEA-4 negative cells grow into basal colonies
As shown on Figure 5.39, SSEA-4−, but not SSEA-4+ cells, were able
to grow into epithelial colonies. These colonies were tested for their
expression of surface markers, both basal and luminal, as well as
the stromal marker CD90. The obtained results underlined the basal
character of these colonies: expression of the basal markers CD49f,
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Figure 5.40: Coexpression between CD49f and SSEA-4. Further coexpres-
sion analysis and cell sorting, using different SSEA-4 antibody
clone (MC813-70), showed that SSEA-4+ cells grew into more
mesenchymal-like cells.
CD49b, CD44, Her2, CD24, expression of the epithelial markers Trop-
2, E-cadherin, Ep-CAM, Her3 and the lack of expression of CD90.
5.7.4 Localization of SSEA-4 in the human prostate epithelium
In addition to the immunohistochemical experiment, SSEA-4 was tes-
ted for coexpression with the basal and intermediate marker CK5.
The basal cells express CK5 at high levels, whereas the intermediate
phenotypes express CK5 with lower intensity. SSEA-4 is expressed
within the fraction expressing CK5 at low levels (Figure 5.42).
5.8 susd2 as a surface marker to distinguish between
subsets at different differentiation levels
Cell sorting of the SUSD2+ and SUSD2− subsets from Du145 and
PC-3 cells shows that SUSD2 enriches monolayer colonies.
SUSD2, described as a mesenchymal stem cell marker by Sivasub-
ramaniyan et al., is expressed at high levels by the stromal mesenchy-
mal prostate cells. However, this work demonstrated that SUSD2 is
expressed in the prostate epithelium and coexpressed with CD49f,
Trop-2 and CD24. Preliminary flow cytometry analysis showed that
SUSD2 did not section the CD49f+Trop-2+ subset (Figure 5.13), but
when used in a costaining with CD24, a subset of very small size was
observed: CD49f+Trop-2+CD24+SUSD2+ (Figure 5.43).
5.9 study on tnap (w8b2)
TNAP is a marker expressed in primary prostate tissues and prostate
cancer cell lines. TNAP was initially a marker of interest, as it is coex-
pressed with CD49f. Further cell sortings of the CD49f+TNAP+ and
CD49f+TNAP− subsets, showed that the epithelial colonies grow in
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Figure 5.41: The SSEA-4− colonies are basal. Cells from the obtained
colonies expressed the basal markers CD49f, CD49b, CD44,
Her2, CD24, the trans-epithelial markers Trop-2, E-cadherin, Ep-
CAM, Her3 and did not express CD90. FCS is shown on the
x-axis.
Figure 5.42: Coexpression between CK5 and SSEA-4. A subset of SSEA-4+
was expressed within the CK5-positive fraction, those subset ex-
pressed SSEA-4 at lower levels in comparison to the CK5−SSEA-
4+ subset.
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Figure 5.43: Coexpression between SUSD2, CD49f, Trop-2 and CD24. The
results show that SUSD2 is coexpressed with CD49f, Trop-2 and
CD24. When used in a costaining with CD24, a subset of very
small size was observed: CD49f+Trop-2+CD24+SUSD2+.
the TNAP− fraction (CD49f+TNAP−). Furthermore, these cells initi-
ated cell division, but their growth has terminated prematurely, due
to potential lack of necessary supplements in the medium. Therefore,
the cells were sorted in different types of media, combining defined
and non-defined conditions. However, none of the used media were
suitable. TNAP is not coexpressed with Trop-2 and this observation
additionally proves that TNAP is not an epithelial marker.
5.10 examination of cancer-derived cell lines
Human prostate cancer-derived cell lines have been used extensively
to study prostate cancer functionally. Different cell lines have been de-
veloped from primary prostate carcinomas or prostate cancer lesions.
PC-3 is derived from bone marrow metastasis, isolated postmortem
from a 62-year-old Caucasian man with poorly differentiated prostate
carcinoma (grade IV). Du145 originates from a nervous system le-
sion of prostate cancer carcinoma of a 69-year-old Caucasian man.
LnCAP is another metastatic cell line, derived from a left supraclav-
icular lymph node metastasis of a prostate carcinoma from a 50-year-
old Caucasian male. From the three, only the LnCAP is androgen-
sensitive and the least tumorigenic. A set of surface markers, which
can potentially distinguish stem/progenitors cells, were tested on
them for this purpose. Three adenocarcinoma cell lines are included
in this study: PC-3, Du145 and LnCAP.
CD24 was expressed on both PC-3 and Du145, but not expressed
on LnCAP cells. SSEA-4 and SUSD2 were expressed in all of the ex-
amined cell lines.
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Figure 5.44: Coexpression between CD49f, SUSD2 and TNAP. TNAP and
SUSD2 are coexpressed with CD49f in different pattern. When
gating on CD49f+ cells, separate subsets of TNAP+ and
SUSD2+ cells were observed. The CD49f− gating revealed
SUSD2+, but not TNAP. TNAP and SUSD2 were not coex-
pressed.
Figure 5.45: Expression of surface markers on LnCAP. The integrins CD51
and CD29 were expressed and the CD41 and CD61 not. CD164
and CD166 were expressed on the LnCAP cells, whereas CD24
and SUSD2 were not expressed. FCS is shown on the x-axis.
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Figure 5.46: PC3 coexpression. CD24 and Trop-2 are expressed on the PC3
cells. Coexpression of these two markers with SUSD2 show that
a small subset of TROP-2 and CD24 is coexpressed with SUSD2.
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Figure 5.47: Clonogenicity of CD24+ and CD24− on Du145. Sorting of the
CD24+ and CD24− cells on DU145 showed similar colony
growth. Both subsets were capable to form colonies, with a
small prevalence of the CD24+ subset.
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Figure 5.48: CD164 coexpression. CD164 is both epithelial and mesenchy-
mal marker in prostate. Trop-2+ subset is coexpressed with
CD164. Further analysis of the epithelial cells shows coexpres-
sion of CD164hi subset with CD26 (luminal marker), whereas
the CD164dim was negative for CD26.
5.11 cd164 as a marker for differentiated epithelial cells
and potential tumor target
Flow cytometry analysis shows that in BPH CD164 is expressed on
both epithelial and stromal (mesenchymal) cells. In the epithelium,
CD164 was expressed in the luminal compartment of human prostate.
Almost 100% of the prostate cancer cell lines PC-3 and DU-145 ex-
pressed CD164, as confirmed by the reactivity of four different anti-
CD164 antibodies N6B6, 67D2, 103B2, and 105A5. The strongest sig-
nal of CD164 expression was observed when the antibody clone 67D2
was used for the staining. Using this antibody clone, a more pro-
nounced expression of CD164 was observed in cancer in comparison
to BPH. PC-3 originates from prostate cancer metastasis in brain and
DU-145 — from metastasis in bone. The observation that both cell
lines express high levels of CD164 suggests that CD164 is strongly
expressed in prostate cancer metastases.
5.12 mesenchymal/stromal cells of the prostate
5.12.1 Surface marker study to identify stromal cells
A set of surface markers was tested on primary prostate and on cul-
tivated (unfractionated) cells to identify potential molecules, which
could separate mesenchymal stromal cells and stromal progenitor
cells.
5.12.2 Cultivated prostate stromal cells express mesenchymal markers
After three passages of culturing, the unfractionated cells were an-
alyzed for expression of surface markers using flow cytometry. Fig-
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CD49f-
Figure 5.49: The CD49f− colony. The CD49f− cells were not capable to grow
into epithelial colonies, but when sorted in mesenchymal me-
dia, they grew into mesenchymal-like colonies. Cells showed
morphology of mesenchymal stem cells with high-spread form
and visible actin filaments.
ure 5.11 shows that the cultivated stromal cells were positive for the
prostate stromal markers CD90 and CD49a [84, 141] and for the mes-
enchymal markers CD146, CD44, CD105, CD29 and CD140b [93, 22,
77, 111], but negative for the epithelial markers Ep-CAM, E-cadherin,
Trop-2 and CD24. In addition, the stromal cells in culture were pos-
itive for TNAP and SUSD2, but negative for SSEA-4. Several anti-
bodies of unknown specificity were also tested to identify specific
markers for prostate mesenchymal cells. The results are shown on
Figure 5.11.
5.12.3 Cells of the stromal compartment are present in the CD49f− subset
Clonogenic assays performed using CnT52 and CnT12 media revealed
that the CD49f− cells, as well as the CD49f+Trop-2− cells were not ca-
pable of giving rise to epithelial colonies. These data were confirmed
in all sorted samples. These two subsets were cell sorted in mesenchy-
mal defined (Knock-out DMEM, supplemented with serum replace-
ment and hFGF) and non-defined complete media (RPMI 1640, sup-
plemented with 10% FCS). Only the CD49f− cells were able to form
stromal colonies at a frequency of 1/10000 (Figure 5.49). The resulting
stromal cells were able to grow with lower proliferation capacity in
comparison weeks after the examination of the colony forming unit
(CFU) capabilities. Furthermore, the cells from the colonies were able
to maintain stromal cell mass in many passages without decline of
growth, but the growth rate was comparably slow.
After three passages of culture, the sorted cells were analyzed for
expression of surface markers using flow cytometry. The obtained
results showed an expression profile, very similar to the one of the
unfractionated stromal cells. The sorted stromal cells were positive
for the prostate stromal and mesenchymal markers, but negative for
the epithelial markers Ep-CAM, E-cadherin, Trop-2 and CD24 (Fig-
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Figure 5.50: Expression pattern of the CD49f− colonies. The sorted CD49f−
stromal cells were positive for the prostate stromal and mes-
enchymal markers (CD13, CD44, CD90, CD105, CD164, CD29,
CD49a, CD49b, CD140b, TNAP, CD146), but negative for the
epithelial markers Ep-CAM, E-cadherin, Trop-2 and CD24. FCS
is shown on the x-axis.
Figure 5.51: Coexpression between CD90 and CD34. CD90 and CD34 were
coexpressed in primary prostate and the CD90+CD34+ cells
were able to grow into stromal colonies (not shown).
ure 5.50). This is in accordance with the experiments performed on
unfractionated cells.
5.12.4 Cells of the stromal compartment are CD90+ CD34+
In a set of additional experiments, stromal cells from primary prostate
were cell sorted depending on their CD90 and CD34 expression pat-
tern and further plated in non-defined complete media (RPMI-1640,
supplemented with 10% FCS). CD90 and CD34 were coexpressed in
primary prostate and the CD90+CD34+ cells were able to grow into
stromal colonies. CD271-positive and CD271-negative cells were also
examined, but stromal colonies were observed in both fractions.
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Figure 5.52: CD49a cells were coexpressed with CD34 and TNAP. Moreover,
he CD49ahi subpopulation enriches CD34+/TNAP(W8B2)+
5.12.5 Prostate stromal cells were able to differentiate into osteoblasts
Cultivated stromal cells in the third passage were examined for their
capability to perform osteoblastic differentiation. After the 14th day,
the cells were positive for alkaline phosphatase and they have ex-
creted calcium hydroxiapatite. These two events are signals for os-
teoblastic differentiation. The process of differentiation into osteoblasts
is typical for the mesenchymal stem cells (MSCs) from bone marrow
and many other tissues.
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Figure 5.53: Osteoblastic differentiation of the mesenchymal colonies. The
prostate stromal mesenchymal cells were able to perform os-
teoblastic differentiation in a sery of experiments, using alkaline
phosphatase assay (b) and hydroxiapatite staining with Alizarin
red (c).
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D I S C U S S I O N
The main goal of this study was to distinguish basal epithelial cell
subsets in the human prostate, possessing different stages of differen-
tiation, through the use of novel surface markers.
It is considered that colonies of different size and cardinality origi-
nate from cells at specific stages of differentiation. Only putative stem
cells are able to give rise to a particular type of clones, termed holo-
clones — the largest colonies with the highest growth capacity and
densely packed cells with a count greater than 500. mesoclones and
paraclones are composed of loosely coupled cells and usually origi-
nate from transit-amplifying cells (Figure 6.1). The aim of this work
is to apply such concepts to analysis of human prostate stem cells and
to identify distinct cell subpopulations within the basal epithelium.
Holoclone Mesoclone Paraclone
Figure 6.1: The three different epithelial colonies, derived from cells at dif-
ferent stages of differentiation.
Various surface markers have been examined and a significant share
of our effort has been directed at the study of adhesion molecules.
Based on the results of this study, the conclusion is that appropri-
ate markers for sectioning of cells at different differentiation levels
within the prostate basal epithelium are those, which participate in
the processes of cell-to-cell and cell-to-matrix adhesion. CD49f was
the most suitable cell-to-matrix adhesion molecule for enrichment of
epithelial progenitor and stem cells. CD49b was excluded, because of
its expression overlap with CD49f. CD49a and CD29 were not found
to be appropriate, as CD49a was expressed by the stromal cells and
CD29 was expressed by the majority of the cells and did not appear
to be a selective marker. CD41, CD51 and CD61 did not lead to a clear
subset, eligible for use in further separation. Moreover, CD51 was co-
expressed together with CD90, which highlights its expression on the
stromal compartment.
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As evident from previous reports, the prostate epithelium expresses
the epithelial markers E-Cadherin, Ep-CAM and Trop-2 [34, 36]. All
of those are cell-to-cell adhesion molecules, typically expressed on
epithelial cells, and their function is to keep the epithelial tissue con-
gruent and dense. Additional research efforts attribute the enrich-
ment of prostate epithelial stem cells to Trop-2 and Ep-CAM [34, 36].
However, the combined use of these two markers is unnecessary, as
they are both expressed by the entire epithelium compartment. The
same applies to E-cadherin as a typical epithelial adhesion molecule,
which was expressed by every epithelial cell of the prostate gland and
responsible for cell-to-cell adhesion and formation of cell-junctions.
Therefore, Trop-2 was selected as a marker for all cells of the epithe-
lium compartment.
As already reported in recent studies, prostate epithelial stem and
progenitor cells could be enriched with the combined use of CD49f
and Trop-2 [34]. However, this and other previously suggested marker
combinations are not sufficient to distinguish the individual differ-
entiation stages of the basal stem/progenitor cells in the course of
their development. Several potential markers exist which section the
CD49f+Trop-2+ subsets and the most promising were CD24 and SSEA-
4 (recognized by the 4A2B8 antibody).
In order to achieve optimal separation, a novel gating strategy was
developed and applied to fractionate stem cell/progenitor subsets. It
proceeds with gating on CD49f-positive cells and setting coexpres-
sion windows in the resulting plot of Trop-2 versus the third marker
(CD24, SSEA-4, SUSD2). This gating method has improved signifi-
cantly the resolution and the separation of the subsets of interest. The
original method, which utilizes a combination of CD49f, Trop-2 and
CD24, produced only two epithelial subsets. The new gating strategy
in contrast allowed us to identify four epithelial subsets, two of which
were able to grow into colonies.
Our study shows that CD24 is not an exclusively luminal marker,
but also expressed by the basal epithelial cells. Within the basal layer,
CD24-positive cells are transit-amplifying (TA) and coexpress Trop-2,
CD49f and CK5, but not AR. In line with their TA nature, CD49f+Trop-
2+CD24+ cells are able to grow in vitro giving rise to basal colonies,
which express a large spectrum of basal and transit-amplifying marker
proteins (CK5/14, p63, bcl-2a, bcl-2b, CD49f, CD49b, Trop-2, and Her2).
Colonies derived from both subsets were able to maintain self-renewal,
although with lower renewal capacity compared to the CD49f+Trop-
2+CD24− subset. Considering that some of the CD24-positive cells
are able to form colonies, these are most probably the CD24+CK5+AR−
cells.
Our results demonstrate that the colonies derived from primary
prostate cells (originating from either BPH or prostate cancer samples)
consist of a mixture of cells at different stages of differentiation. Most
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of those cells acquire a transit-amplifying (basal) phenotype, which
can be explained with the expression of many basal markers by all
cells and additionally CD24 by the majority of cells. The colonies did
not express the other markers of interest, such as SUSD2 and SSEA-
4, illustrating that these two molecules are not expressed by transit-
amplifying cells, but probably by cells on later or parallel stage of
differentiation. In addition, the presence of CK18 at low levels in the
colonies suggests that some of the cells have differentiated to ones
with intermediate (luminal) phenotype.
The transit-amplifying (TA) progenitor cells are localized in the
basal layer, possess limited capacity to grow and renew, express basal
markers and do not express luminal markers at all or express them
modestly.
CD24+ cells were found to be localized in the basal layer (illus-
trated on Figure 5.21). A small subset of CD24+ cells are co-expres-
sed with CK5 and not co-expressed with the androgen receptor (Fig-
ure 5.36 and Figure 5.38). In addition, CD24+ cells are able to grow in
basal/TA colonies (Figure 5.29 and Figure 5.30), which mainly consist
of TA cells. CD49f+Trop2+CD24+ is a basal subset, because it con-
tains cells capable of growing into colonies (only basal stem/progen-
itor cells have such capabilities) and moreover, the resulting colonies
possess a basal character (Figure 5.29 and Figure 5.30).
In addition, our experiments show that the CD49f+Trop2+CD24+
cells are transit-amplifying. They are localized in the basal layer and
possess a weaker groth capacity compared to the CD49f+Trop2+CD24−
subset. When cultured in a serum-free, calcium-low conditions, pro-
state epithelial cells grow into colonies, consisting of TA cells predom-
inantly [127, 14, 71, 18]. We prove that these cells possess the pheno-
type CD49f+Trop2+CD24+CD49b+CK5++CK18low. Interestingly, the
observed E-cadherin expression level is low, which is explained by
the low-calcium conditions, in which the cells are cultivated, as E-
cadherin is calcium dependent [18].
The identification of cell subsets responsible for epithelium lineage
differentiation in a mature prostate may provide an insight to under-
standing the mechanisms of cell differentiation in BPH and prostate
cancer.
The experimental results support the concept of a refined discrim-
ination between basal and luminal epithelial cells. The existence of
an intermediate subset, responsible for the transition from the basal
to the luminal epithelial compartments, is reported. The most com-
monly used model describing the localization of the prostate stem
cells suggests that the ES/P cells reside in the basal cell compart-
ment [20]. These cells divide and amplify, before transitioning to a
state of maturation towards terminally differentiated basal progeni-
tors, termed transit-amplifying (TA)/intermediate cells. They are lo-
calized within the basal layer, express a basal cell phenotype and
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acquire expression patterns of luminal cells [20]. Different develop-
mental models of intermediate cells and their localization exist. Tokar
et al. propose a model to distinguish cells of the basal compartment
(PS/P cells and mature basal cells) and the luminal compartment (lu-
minal cells and intermediate cells) [120]. According to this view, the
most mature basal cells play a crucial role in maintaining the integrity
of the prostate and support of luminal cell differentiation [11, 62].
Isaacs propose a model of differentiation, in which putative stem
cells divide and differentiate into transit-amplifying (TA) progenitor
cells that give rise to intermediate cells of the luminal compartment.
These cells possess both basal and luminal characteristics [48]. Ac-
cording to this view, the luminal intermediate cells are the direct
progenitors of terminally differentiated secretory luminal cells. There-
fore, intermediate cells are expected to reside in both compartments,
depending on their differentiation level. The differentiation from the
basal to the luminal compartment is associated with the loss of basal
markers and the acquisition of luminal markers. The qPCR results
presented in our study suggest that the selected surface markers are
useful to distinguish between poorly-differentiated progenitors and
intermediate basal (transit-amplifying) cells.
It is known that basal, luminal and intermediate cells can be dis-
tinguished based on their cytokeratin expression patterns. In this
work is shown that the combined use of different surface markers
enables the discrimination between subsets of different differentia-
tion stages in prostate basal epithelium. In this study, different com-
binations were utilized, including CD49f, Trop-2, CD24, SSEA-4. Us-
ing the transit-amplifying marker CD24, we show that CD49f+Trop-
2+CD24− and CD49f+Trop-2+CD24+ cells are localized within the
basal compartment of human prostate, whereas CD49f−Trop-2+CD24+
cells are localized in the luminal epithelium. Interestingly, CD49f−
Trop-2+CD24− cells express a phenotype, similar to that observed in
the basal epithelium.
CD49f+Trop-2+CD24+ and CD49f−Trop-2+CD24+ cells display an
expression profile closer to terminal differentiation in comparison
to the CD49f+Trop-2+CD24− cells, as verified by the fact that they
express higher AR and CK8/18 levels and lower CK5 levels than
CD49f+Trop-2+CD24− cells. Cells of the CD49f+Trop-2+CD24+ sub-
set express CK5 and are able to give rise to basal colonies. Together
with the fact that CD24 is localized in the basal layer of the secre-
tory acini, these data suggest that CD49f+Trop-2+CD24+ cells are
localized within the basal layer. Moreover, in vitro cultivation of these
cells, as well as cells of the CD49f+Trop-2+CD24+ subset, generates
colonies whose cells predominantly exhibit the CD49f+Trop-2+CD24+
phenotype. The composite phenotype of this cell subset resembles
the phenotype of the transit-amplifying cells, which are localized
in the basal layer, but are characterized by lower clonogenic and
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proliferative properties and lower levels of CK5 expression. In con-
trast to CD49f+Trop-2+CD24− cells, CD49f−Trop-2+CD24+ cells dis-
played properties closer to intermediate cells, which are localized in
the luminal layer. These traits include the expression of the lumi-
nal markers CK8/18, the expression of CK17 and PSCA, as well as
the absence of any proliferative capacity. Cells of the non-clonogenic
CD49f−Trop-2−CD24− subset expressed low levels of luminal mark-
ers and high levels of the basal marker p63, a molecule which is not
expressed in the epithelial stem cells. This indicates that this sub-
set consists of mature basal cells. More experiments need to be per-
formed to confirm that observation and to examine this subset fur-
ther. Lack of expression of CD49f by the cells of this subset is a major
drawback in concluding its definite basal localization. Based on the
findings in this study, it is proposed that the CD49f+Trop-2+CD24+
and CD49f−Trop-2−CD24− subsets originate from the more primitive
CD49f+Trop-2+CD24− subset, which is characterized by cells with
the highest clonogenic capacity and the strictest basal phenotype (Fig-
ure 6.2) [92].
CD49f+T2+CD24-f T CD49f+T2+CD24+f T
luminal
CK5++
blc-2+
CD49f-T2+CD24+f 2
CK18+CK8+
basal CD49f-T2+CD24-f 2
basal cells
Low differentiated 
progenitors
Early intermediate
(transit-amplifying) 
cells
Late intermediate
cells
Terminal differentiation (basal to luminal)
CK5++CK18low
Figure 6.2: Model of the human prostate epithelial lineage development,
based on differential surface marker expression.
The CD49f+Trop-2+CD24+ cells in human BPH and cancer have
colony-forming and proliferative potential [92], which raises the ques-
tion about the function and ontogeny of these cells within human
prostate epithelium. The role of CD24 in benign diseases has not been
identified. In prostate and breast cancer CD44+CD24− subset shows
phenotype typical for stem cells. Nevertheless, CD24+ cells are as-
sociated with poor prognosis in prostate cancer [61], breast cancer
[2, 81] and other epithelial malignancies [60]. Moreover, recent stud-
ies identified CD24+ tumor-initiating cells in solid tumor cancers [30],
colorectal cancer [138], liver cancer [67] and pancreatic cancer [69].
As CD24 expression was detected in the basal and luminal layers,
it is likely that the acquisition of CD24 in the basal layer reflects the
onset of differentiation into luminal cells. However, CD24+ cells that
reside in the basal layer show a less pronounced clonogenic capac-
ity compared to CD24− basal cells. These features, together with the
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distinct expression profiles of key markers, indicate that CD24+ cells
in the basal layer are the transit-amplifying cells that are localized at
the interface between stem and luminal cells. CD24 is an adhesion
molecule, which alters cell adhesion and stimulates migration and
proliferation. This molecule may participate in the process of migra-
tion of cells from the basal to luminal layer. In agreement with this
concept is the fact that CD24 increases the motility of tumor cells [8].
However, the physiological function of CD24 in normal and benign
epithelium remains unknown.
The function of SSEA-4 on epithelial cells and tissues has not been
studied sufficiently. SSEA-4 is reported to be highly expressed on
the differentiated corneal epithelium and it is a negative marker for
human limbal stem/progenitor cells [123]. Similar results are here re-
ported for human prostate, regarding its epithelial stem/progenitor
cells. Our work shows that SSEA-4 is expressed on human prostate
epithelium, as well as that SSEA-4+ cells are not clonogenic and ex-
pressed between the basal and luminal layer. This suggest that this
marker is expressed by a subset of intermediate cells, which are pass-
ing through luminal differentiation. These cells are not able to grow
into colonies, but still do coexpress CD49f and Trop-2.
In this project, no correlation and statistically significant difference
between BPH and prostate cancer was found concerning surface mar-
ker expression and clonogenicity. All examined markers were expres-
sed in both diseases and their expression levels varied on a tissue
basis. Prostate cancer is a heterogeneous disease and a correlation
between the expression of surface markers and cancer development
is difficult to assess.
Epithelial-mesenchymal transition (EMT) is regarded to play an im-
portant role in the development of BPH and prostate cancer. It is also
considered to be linked to the stem cell signatures in prostate. EMT
involves the participation of adhesion molecules, therefore study of
these molecules within basal layer is beneficial. CD24 is a cell-to-cell
adhesion molecule, which may functionally participate in the epithe-
lial development of normal human prostate, as well as in BPH and
prostate cancer.
In addition to the epithelial markers, many mesenchymal ones
have been expressed on human prostate cells. CD90 was reported to
be expressed on the reactive stroma of human prostate cancer [141].
However, it is expressed by the mesenchymal stroma of the normal
and prostate BPH as well. In this work, it is shown that the mes-
enchymal stromal colonies grow from the CD49f− subset, but not
from the CD49f+. In line with this observation, the CD49f+TNAP+
subset failed to grow into mesenchymal colonies in several media,
even though some cells have initiated a couple of divisions. These
cells were suggested to be endothelial progenitors, but they were out
of scope of the project and were not examined further. Comparing
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these data to the results for the epithelial subsets, these were the
CD49f+Trop-2−CD24− cells (CD49f+Trop-2−CD24−TNAP+), which
were not able to grow into mesenchymal colonies.
The findings in this study indicate a hierarchy of cells with various
differentiation capacities within the adult prostate gland, in which
developmentally distinct and prospectively separable stem and differ-
entiated progenitors are involved. The ability to isolate these distinct
populations provides a new basis to investigate the prostate epithelial
stem/progenitor cell differentiation and to study the precise stage, at
which aberrant BPH and prostate cancer cells preferentially develop.

7
O U T L O O K
Future research on the function of CD24 and SSEA-4 in human prosta-
te could open up interesting opportunities and bring an insight on the
potential mechanisms of development of BPH and prostate cancer.
Trivial targeting and downregulation of markers expressed on both
normal and cancerous prostate tissues would not prevent the disease
from developing; rather, it might reveal previously unknown mecha-
nisms. This prompts the need to explore the underlying mechanisms
which govern the development of the disease.
The process of epithelial-mesenchymal transition (EMT) is regarded
to take an important role in benign prostate hyperplasia and prostate
cancer development, because EMT is directly linked to the stem cell
signatures in prostate cancer. Therefore, it is important to investigate
potential EMT markers as possible therapeutic targets. It has been
known that adhesion markers are involved in the development of
EMT. Various adhesion molecules have been studied in this work and
the knowledge of their expression pattern in human benign prostate
and prostate cancer will contribute to future EMT research efforts.
Further studies on the role of these markers in EMT and their exact
function are required.
This project lays the groundwork for future research in the field of
prostate cancer stem cell biology and prostate oncology. Further ex-
periments with cancer cell lines and primary prostate cancer tissues
are planned. These studies will focus on several aspects of prognostic
and therapeutic relevance. One goal is to distinguish normal and can-
cer stem cells according to differential surface marker expression and
to define prospective clinical and diagnostic markers. Another impor-
tant aim is to discriminate between benign and tumor stem cells by
their phenotype and propose candidate antibodies, designed to tar-
get cancer stem cells specifically. Such antibodies may either directly
eliminate the cancer cells, or may be effective after optimization of
their Fc regions and emerge as promising candidates for therapy. An
additional aspect of future research efforts will be the identification
of surface markers for monitoring of the epithelial-mesenchymal tran-
sition process.
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Some ideas and figures have previously appeared in the following
publications:
Publications
• Petkova N, Hennenlotter J, Sobiesiak M, Todenhöfer T, Scharpf
M, Stenzl A, Bühring HJ, Schwentner C. Surface CD24 distin-
guishes between low differentiated and transit-amplifying cells
in the basal layer of human prostate. The Prostate. 2013.
– Text and figures from this manuscript appear in Chapter 5
and Chapter 6.
• Sivasubramaniyan K, Daniela L, Ghazanfari R, Sobiesiak M, Ha-
richandan A, Mortha E, Petkova N, Grimm S, Cerabona F, de
Zwart P, Abele H, Aicher WK, Faul C, Kanz L, Bühring HJ. Phe-
notypic and functional heterogeneity of human bone marrow-
and amnion-derived MSC subsets. Annals of the New York Aca-
demy of Sciences. 2012.
– Text and figures from this manuscript appear in Chapter 2
Posters
• Petkova N, Hennenlotter J, Grimm S, Cerabona F, Stenzl A, Büh-
ring HJ. Isolation and surface marker characterization of ep-
ithelial and stromal stem cells in benign prostate tissue. Biostar
Congress, 2010. Published in: Tissue Engineering Part A. Vol. 17.
2011.
– Text and figures from this poster appear in Chapter 5
• Petkova N, Hennenlotter J, Schwentner C, Todenhöfer T, Grimm
S, Cerabona F, Schilling D, Stenzl A, Bühring HJ. Differential
isolation and surface marker characterization of epithelial and
stromal stem cells in benign prostate tissue. European Associa-
tion of Urology Congress, 2011. Published in: European Urology
Supplements. 2011.
– Text and figures from this poster appear in Chapter 5
• Petkova N, Hennenlotter J, Todenhöfer T, Sobiesiak M, Aufderk-
lamm S, Scharpf M, Stenzl A, Bühring HJ, Schwentner C. 899
Surface CD24 distinguishes undifferentiated from transit-ampli-
fying cells in the basal layer of the human prostate. Uropean
Association of Urology Congress, 2013. Published in: European
Urology Supplements. 2013.
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